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Colorectal Cancer (CRC) is the third most common and leading cause of cancer death in 
the United States. Although CRC screening can prevent and detect CRC at an early stage, about 
35% of Americans are not screened. Despite the recent increase in screening, people with lower 
SES and those who live in rural areas have lowest screening.  In rural areas, a common obstacle 
for screening is the long trips for health services which is associated with advanced CRC.  
Moreover, surgery is a substantial part of CRC treatment since stages I-III and some 
metastatic CRC (mCRC) patients are treated with surgery. Up to 25% of patients who undergo 
surgery get readmitted to the hospital due to several factors which costs $300 million annually. 
Prior studies showed some variations in CRC treatment between rural and urban patients. 
The purpose of this study was to assess the association between rural-urban status and 
CRC screening, stage at diagnosis and the receipt of CRC surgery. There were three specific aims: 
1) To assess the impact of rurality on CRC screening, 2) To assess the impact of travel time on the 
stage of CRC diagnosis, and 3) To evaluate rural-urban differences in healthcare utilization.  
We conducted analyses using data from Blue Cross Blue Shield of Nebraska (BCBSNE) 
between 2012 and 2016. For Aim 1, the study population included BCBSNE members aged 50-64 
years with average-risk CRC. For Aim2, the study population included BCBSNE members aged 50-
64 years with average-risk CRC. For Aim 3, the study population consisted of CRC patients between 
the ages of 19-65 years old who had CRC surgery during the study period.  
Claims data were used to ascertain the CRC screening, diagnosis, receipt of surgery and 
hospital readmission using ICD and CPT codes. Rural-urban status was based on the Rural-Urban 
Commuting Area Codes and travel time between the residence and the provider facility was 
calculated using Google Map. For Aim 1, prevalence rates for FOBT and colonoscopy were 
calculated and compared using X2-test. Univariate and multivariate logistic regression analyses 
were performed to assess the relationship between the independent variables and CRC screening 
test.  For Aim 2, we used Wilcoxon rank-sum tests for continuous variables and X2-tests for 
categorical variables and we adjusted for covariates using logistic regression. For Aim 3, 
Readmission and surgery status were estimated using multivariate logistic regression.   
 There was no significant difference between rural and rural residents in colonoscopy use. 
However, after adjustment, rural residents were 47% more likely to use FOBT. Patients who do 
not use preventive services were 2.80 more likely to present with mCRC and urban residents were 
3.50 times more likely to receive mCRC. The fact that 12% of our population presents with mCRC 
suggests some non-compliance with screening guidelines. Therefore, we recommend removing 
barriers that prevent rural patients from receiving screening colonoscopy and thus increase early 
detection of CRC. Until these obstacles have been lessened, screening with more convenient tests 
is encouraged. The use of mailed FOBT test is easy and more accessible.  
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CHAPTER 1: INTRODUCTION  
Epidemiology of Colorectal Cancer in the US 
Burden of Colorectal Cancer  
Colorectal cancer (CRC) is a malignant tumor of the large intestine or rectum. It is the third 
most common cancer in the US preceded by lung and breast cancers in women and lung and 
prostate cancers in men.1 CRC is also the third leading cause of cancer deaths in the US.2 According 
to the Surveillance, Epidemiology, and End Results (SEER), in 2017 there will be 135,430 new cases 
of CRC and 50,260 deaths from CRC.3 The total annual cost of care for CRC is projected to increase 
between 2010 and 2020, from $6.0 billion to $7.2 billion for the diagnosis, from $4.0 billion to 
$4.9 billion for the treatment and from $4.3 billion to $5.3 billion for the end-of-life care.4 
Overall, the lifetime risk of developing CRC is about 1 in 21 for men and 1 in 23 for 
women.5,6 As shown in Figure 1, since 1975, the risk of developing CRC has varied by gender, with 
males having consistently higher incidence rates than females, possibly due to higher prevalence 
of the risk factors such as physical inactivity and limited consumption of fruits and vegetables.6-9  
CRC Incidence  
For both males and females, the incidence rate has steadily declined between 1975 and 
2013 from 68.45 per 100,000 to 42.90 per 100,000 among males and from 53.66 per 100,000 to 
32.42 per 100,000 among females.5 According to Figure 2, the incidence rates declined among all 
groups with Whites and Blacks had the largest decline.5 Before 1985, Whites had higher incidence 
rates than Blacks, but the trends started to reverse in 1985 when rates for both Whites and Blacks 
started declining. This decline was sharpest among Whites—a decrease from 67.2 per 100,000 in 
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1985 to 36.0 per 100,000 in 2013, compared with Blacks – from 64.1 per 100,000 to 46.3 per 
100,000.10 The decline occurred with a corresponding increase in colonoscopy screening among 
the Medicare population.11,12 
 
Figure 1. Trends in Age-Adjusted Incidence Rates for Selected Sites by Gender, United States, 1975 
to 20126 
CRC Mortality 
Mortality data showed overall consistent declining trends for both Blacks and Whites with 
a steeper declining curve among Whites.2 Starting in 1988, Whites had declining death rates – 
from 25.1 per 100,000 to 14.1 per 100,000, while Blacks showed less decline – from 29.2 per 
100,000 to 19.3 per 100,000. The rapid decline in death rates among Whites occurred due to an 
increase in early detection and increasing polypectomy rates.2 Other races have had lower 
mortality rates including Hispanics and Asian/Pacific Islanders. 
As shown in Figure 3, the time trend of death rate has a distinct pattern by gender. The 
death rate among males peaked around 1945 with a rate of 36.0 per 100,000 and remained steady 
until around 1985 when the rate started to decrease gradually to 17.34 per 100,000 by 2012; 
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among females the peak was also around 1940, but afterwards the rate immediately declined 
consistently to reach 12.12 per 100,000 by 2012.6 Declines in both incidence and death rates of 
CRC have been attributed to the decline in the prevalence of risk factors and the increased 
screening.2,6,13 Recently, the sharp decline in the mortality rate of CRC (1990-2012) is due to 
increases in colonoscopy screening rates.2,14 
 
Figure 2. Trends in Age-Adjusted Incidence and Death Rates for Colorectal Cancer by Race, United 
States, 1975 to 201310 
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Figure 3. Trends in Age-Adjusted Death Rates for Selected Sites by Gender, United States, 1930 to 
20126 
CRC Incidence and Mortality Rates by Age Group 
Like most other cancers, incidence and death rates of CRC increase with age. Overall, 90% 
of new cases and 94% of deaths occur in individuals 50 years and older;2,15 in fact, the incidence 
rate of CRC is more than 15 times higher in adults 50 years and older than those between 20 and 
49 years. While the CRC death rate has declined in both older and younger age groups, the decline 
was greater for those 65 years and older than those between 50 and 64 years old.15,16 Specifically, 
more than 70% of the decline in death is among individuals 65 years and older.2 This pattern might 
be partly explained by higher CRC screening rates among individuals 65 years and older.16 In July 
2001 the Congress enacted a law to entitle Medicare beneficiaries who are at average risk of 
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developing CRC to colonoscopy screening every ten years.11,12 By 2005, 47% of people 65 years 
and older had been screened compared to only 33% of those 50-64 years of age.12 
CRC Incidence and Mortality Rates by Geographic Location 
Incidence and death rates of CRC vary by geographic location.14,17 Overall, the age-
adjusted incidence rates are highest in the Midwest and lowest in the Northeast. For instance, the 
lowest rate was in District of Columbia while the highest was in Kentucky.17 As shown in Figure 4, 
CRC mortality rates are highest in the South and Midwest in both White and Black men and 
women.14 In the northeast regions, where mortality rates have decreased, there has been an 
increased utilization of CRC screening tests. Other factors that have contributed to such regional 
variations include access to screening and treatment facilities, which is also influenced by regional 
differences in socioeconomic status.17-19 Therefore, the need for a study that assesses the 
distribution of screening utilization while controlling for socioeconomic status is warranted.   
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Figure 4.  Colorectal Cancer Death Rates by State, 2006-201017 
Risk and Protective Factors for Colorectal Cancer  
Overview 
Factors that increase the risk of CRC are older age (≥65 years old), meat consumption, 
alcohol intake, smoking, and obesity, while factors that reduce the risk are consumption of fruit 
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and vegetables, physical activity, aspirin intake and consumptions of other nutrients (e.g., fiber 
and dairy products).20,21 In this section, these factors are discussed in details.  
Average Risk Population  
Average risk population is individuals who are at least 50 years old, with no personal 
history of CRC or adenomatous polyps, no personal history of inflammatory bowel disease, no 
family history of CRC or polyps or a known family history of a hereditary CRC syndrome such as 
familial adenomatous polyps or Lynch syndrome.22   
Age         
The mechanism behind the increasing incidence rate of CRC with age is related to the 
aging process.23 In a normal colorectal epithelial cell, hypermethylation (i.e., an addition of methyl 
groups) of tumor suppressor genes is associated with increased cell proliferation and 
differentiation, a characteristic that precedes the development of cancer. The hyperproliferation 
(i.e., increase in cell divisions) accumulates over time and manifests at an older age. Additionally, 
as explained below, tumorigenesis involves genetic alterations that take decades to manifest into 
CRC which also explains the role of age as a potential CRC risk factor. 
In the U.S., the risk of CRC increases with age regardless of gender or race.6 However, 
recent incidence rate trends show that the disease is increasing among people younger than 50 
years of age and slightly decreasing among those 50 years and older. Of the various types of CRC, 
proximal colon cancer, or a tumor located in the right and transverse colon, increases with age 
from 26-27% in the youngest age group (younger than 50 years) to 49-56% (80 years and older).2 
In addition, people younger than 50 years of age had the lowest annual percentage changes in 
incidence rates of proximal colon cancer between 2001 and 2010 (-0.2%) compared to the older 
age groups (ages 50-64 years: -2.8% and ages ≥65 years:-2.7%). On the other hand, rectal cancer 
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is more common among younger individuals. While only 1 in 5 rectal cancer patients 80 years and 
older presents with the disease, 2 in 5 rectal cancer patients younger than 50 years present with 
the disease.  
Dietary Factors 
Increased fruit and vegetable consumption has been associated with lower risk of CRC.20,21 
Vegetables contain substances with antioxidant properties such as carotenoids and ascorbate as 
well as bioactive compounds such as flavonoids.21 Another component of vegetable is folic acid, 
which is also available as a nutritional supplement. Folic acid is a water-soluble vitamin B, which 
plays a vital role in the transfer of one-carbon during biosynthesis of purines and thymidylate 
during DNA synthesis.24 Folate is also an intracellular coenzyme (5, 10- 
Methylenetetrahydrofolate) that is needed during the conversion of deoxyuridylate to 
thymidylate which is oxidized to 10-formyltetrahydrofolate for purine synthesis. Due to its role in 
DNA synthesis and stability, folate reduces DNA damage and protects against CRC 
development.20,25  
Similarly, calcium intake and dairy food might lower risk of CRC through a reduction in cell 
proliferation. Multivitamin supplements, non-steroidal anti-inflammatory drugs, and hormone 
replacement therapy contribute to the reduction of CRC as well.21 The anticarcinogenic properties 
of these compounds reflect their preventive effect, which has been found in studies such as the 
Health Professional Study, the Nurses’ Health Study and the Seventh Adventists Study.26,27 
In contrast, increased consumption of red and processed meat is associated with an 
increased risk of CRC.20 Heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs) 
are chemicals produced when meat is cooked at high temperature or directly over open flame.28  
HCAs are produced as a result of the reaction between amino acids, sugars, and creatine at a high 
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temperature. PAHs are produced when fat from meat drips into the fire and form flames; these 
flames contain PAHs, which remain on the surface of the meat.28 The Nurses’ Health Study found 
a 2.5-fold increase in risk among women who consumed meat frequently compared to women 
who rarely ate meat. Likewise, the Male Health Professional Study showed that men with 5 or 
more servings per week of meat had a statistically significant higher risk of CRC.29  
Obesity  
A large geographic variation in CRC incidence rates reported in migration studies suggests 
the roles of different lifestyle factors such as obesity, which plays a significant role in the etiology 
of CRC. Previous studies suggested that obese individuals are up to 60% more likely to develop 
CRC compared with normal weight individuals.30 The association is stronger among colon cancer 
patients when compared with rectal cancer patients. Additionally, the risk tends to be higher 
among obese men compared with obese women.31    
Cigarette Smoking, Alcohol Intake, and Other Factors  
Tobacco smoking is associated with both an increase in incidence and mortality of CRC.32 
Compared to non-smokers, smokers are 2-3 times more likely to develop premalignant 
adenoma.33 Likewise, daily alcohol intake is linked to an increase of about 40-70% in the risk of 
CRC occurrence.34,35 Together, alcohol and smoking might act in synergy to increase CRC risk. 
Moreover, insulin and insulin-like growth factors contribute to the regulation of human growth 
and development and thus promote cell proliferation and angiogenesis while preventing 
apoptosis in the colon. Finally, individuals diagnosed with type-2 diabetes, those who are 
physically inactive, and those who are overweight have higher risk of CRC.36  
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High-Risk Population  
High-risk population is individuals who had a personal history of CRC or adenomatous 
polyps, personal history of inflammatory bowel disease, family history of CRC or polyps or a known 
family history of a hereditary CRC syndrome such as familial adenomatous polyps or Lynch 
syndrome.22   
Personal History of Inflammatory Bowel Disease 
Individuals with diseases that cause long-term inflammation of the colon are at increased 
risk of CRC.37 The two Inflammatory Bowel Diseases (IBDs) associated with the development of 
CRC are Crohn’s disease and ulcerative colitis. While Crohn’s disease affects the bowel wall, 
ulcerative colitis involves inflammation of the bowel mucosa.38 Regardless of one’s age, people 
diagnosed with IBDs, have 4-20 fold the risk of CRC development compared with those without 
IBDs.39 
Personal History of Adenomatous Polyps 
Almost all CRCs develop from precursor benign polyps, primarily adenomatous polyps.40,41 
Adenomatous polyps that are large (>1cm), with high-grade dysplasia and with villous features 
are more likely, if not removed, to develop into CRC within 5-10 years.42 In the average US 
population, the lifetime risk of developing adenomatous polyps is 19%.38 CRC is a largely 
preventable disease since colonoscopy with polypectomy is associated with up to 76% reduction 
of the occurrence of CRC43 and a 53% decrease in CRC mortality.44 
Family History of Colorectal Cancer or Adenomatous Polyps and Inherited Genetic Risk 
Approximately one in five individuals diagnosed with CRC have at least one family 
member with adenomatous polyps or CRC.38,45 Those with first-degree relatives, who were 
diagnosed with adenomatous polyps or CRC, are more likely than those with non-first-degree 
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relatives to develop the disease. Both environmental, as well as genetic factors, contribute to the 
occurrence of CRC among family members with a history of polyps and CRC. Furthermore, CRC 
due to inherited genetic risk occurs in 5-10% of the CRC patients. The two common inherited 
conditions are Familial Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis CRC (HNPCC). 
Both will be explained in details in the pathogenesis section below.  
Pathogenesis of Colorectal Cancer 
CRC Pathways and Tumorigenesis 
Fearon and Vogelstein were among the first to describe colorectal tumorigenesis, or the 
process of cancer formation, by defining the stages of disease development.46 They proposed a 
genetic model of colorectal tumorigenesis or the adenoma-carcinoma pathway for the occurrence 
of CRC (Figure 5). Fearon and Vogelstein showed four distinctive genetic alterations that are 
pertinent to CRC; the mutations of ras gene (i.e., activation of oncogene) and the deletion of 
chromosomes 5q, 17p, and 18q (i.e., inactivation of tumor suppressor genes). These alterations 
accumulate over time, and the percentage of alterations tends to increase from approximately 
25% during early adenomas to 49% in intermediate adenomas. Over 90% of carcinomas have two 
or more alterations. Although these stages can occur in any order, Figure 5 illustrates the most 
typical order of CRC tumorigenesis as it consistently occurs in populations with different race and 
ethnicity, and in various geographic locations.20,46 
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Figure 5. Genetic Model Of Colorectal Tumorigenesis46 
 During the early stage of tumorigenesis, the Adenomatous Polyposis Coli (APC) gene, 
which is located in chromosome 5q, undergoes germline or somatic mutation. This loss or 
silencing of the APC gene results in the change of the normal epithelium into the 
hyperproliferative epithelium. For the development of early adenoma (i.e., adenoma with a size 
of ≤ 1cm), an additional clonal expansion is implicated and results in DNA-hypo-methylated 
adenomas. Further mutations in the K-ras gene result in an intermediate adenoma (i.e., > 1cm) 
but without the foci for carcinoma. Further gene mutation or loss on chromosome 18q or tumor 
suppresser gene P53 will subsequently lead to late adenoma (i.e., > 1cm) with the carcinoma foci. 
Eventual accumulating loss of the tumor suppressor gene leads to carcinoma and then metastasis. 
CRC is a heterogeneous disease, with four distinct molecular pathways that lead to CRC, 
as described by Potter et al. (Figure 6).20 The first is the adenoma-carcinoma sequence, where the 
APC gene is mutated. The second is the Lynch syndrome pathway, where the DNA mismatch 
repair gene is lost either through inherited or acquired mutation or methylation. The third is the 
dysplasia-carcinoma sequence, where CRC develops through ulcerative colitis (no APC mutation 
or polyp formation). Fourth and final is the hypermethylation silencing of the estrogen receptor 
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genes, which is more common in sporadic CRC. These different pathways have an impact on 
disease progression, screening, and treatment. The US Preventive Services Task Force (USPSTF) 
guidelines suggest that high-risk groups such as those diagnosed with Lynch syndrome or FAP 
should be screened at an early age, which typically occurs ten years earlier than the general 
population.47,48    
 
Figure 6. Colorectal Cancer Pathways20 
CRC tumorigenesis consists of three main stages: initiation, progression, and 
transformation (Figure 7).49,50 At the initiation stage, some normal colon stem cells will outgrow 
adjacent cells due to various stimuli (genetic or environmental). Because of this increased 
abnormal cell growth, normal cells become hyperplastic (i.e., tissue growth due to excessive 
proliferation while maintaining the same cell structure as normal cells); with more proliferation, 
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hyperplastic cells become dysplastic cells (i.e., a premalignant tissue characterized by an increased 
cell number with nuclear abnormalities) (Figure 7). During the progression stage, dysplastic cells 
will undergo additional genetic events that will result in the development of abnormal growth in 
the lining of the colon; this abnormal yet benign tumor is called a polyp and is considered an early 
adenoma.  It takes several years during the last stage, the transformation stage before advanced 
adenoma develops. If the advanced adenoma or polyp is not removed it will lead to a malignant 
tumor.51  
 
Figure 7. The Sequences from Normal to Cancer Tissue52 
Classification of CRC 
Based on personal and family history, CRC is classified into syndromic and sporadic. 
Approximately 15-30% of CRC is syndromic or hereditary and occurs in persons with first- or 
second-degree relatives who have had CRC.45,53 The two most common syndromic CRC cancers, 
which are associated with increased risk of CRC occurrence, are FAP and HNPCC (i.e., Lynch 
Syndrome). On the other hand, sporadic CRC, which accounts for 70-85% of CRC cases, occurs 
among average-risk persons with no genetic risk factors. Somatic CRC develops due to somatic 
mutations over the course of the lifespan through the exposure to environmental and lifestyle 
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risk factors. The rate of disease progression is higher in syndromic than in sporadic CRC. For 
instance, the likelihood of developing adenoma among individuals with a defect in the DNA 
mismatch repair gene (DNA MMR), an inherited mutated gene among patients with Lynch 
syndrome, is not different from the general population. However, once the adenoma has 
developed, progression to carcinoma is faster than the progression among sporadic CRC patients 
due to the irreparable damage caused by DNA MMR defect.20  
CRC Screening  
The Available Screening Tests 
CRC screening is recommended for average-risk individuals (i.e., no history of CRC, polyps 
or inflammatory bowel disease) starting at age 50.48,54 CRC screening tests include three stool-
based tests, four imaging tests, and two endoscopy tests. The stool tests are gFOBT, FIT and fecal 
DNA test. The imaging tests are double-contrast barium enema (DCBE), computed tomographic 
colonography (CTC), magnetic resonance colonography (MRC) and capsule endoscopy.47 The 
endoscopy tests are flexible sigmoidoscopy (FS) and colonoscopy. The most commonly used tests 
in the US are colonoscopy, FS, FIT, and high-sensitivity gFOBT.55,56 The current National 
Comprehensive Cancer Network (NCCN) guidelines recommend the following screening methods 
and frequency: annual high sensitivity guaiac-based fecal occult blood test (gFOBT) or fecal 
immunochemical test (FIT); FS every five years with stool blood tests (FOBT or FIT); and 
colonoscopy every ten years.43,48,57 
Effectiveness of Screening Tests 
CRC screening tests can be classified according to their effectiveness in detecting 
adenomatous polyps, and CRC.43 While FS, colonoscopy, DCBE, and CTC can detect both 
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adenomatous polyps and cancer, gFOBT, FIT, and stool DNA test with high sensitivity can only 
detect cancer. Tests that are effective in detecting both are more invasive, require bowel 
preparation, associated with more complications (e.g., perforation and bleeding) and are 
costly.43,47 
CRC screening can prevent cancer with the use of polypectomy and can detect CRC at an 
early stage.43 The National Polyp Study found that polypectomy could decrease up to 76% of CRC 
incidence.58 Subsequent studies corroborated such findings but with a lesser reduction in CRC 
incidence.59,60 The National Polyp study also estimated a reduction of 53% in CRC deaths due to 
polypectomy.44 Many other studies have found decreased mortality with screening.47 Taken 
together, evidence suggests a reduction in both incidence and mortality rates with CRC screening. 
It should be noted, however, that the effectiveness of screening using colonoscopy varies 
between specialties.61-64 Non-gastroenterologists are significantly less likely to detect and remove 
polyps compared with gastroenterologists. Specifically, general surgeons are 20% less likely, and 
internists are 7% less likely to detect and remove polyps compared with gastroenterologists.61 
This study, however, relied on physician’s specialty without considering the training level on 
colonoscopy use. Nonetheless, failure to detect polyps, a precursor lesion of CRC, undermines the 
main purpose of screening using colonoscopy, which is to prevent CRC through polypectomy.  
Diagnosis 
Clinical Diagnosis  
CRC is diagnosed histologically through biopsy taken during endoscopy.65 Because 2%-4% 
of patients present with synchronous tumors, complete colonoscopy or CT colonography must be 
performed to detect additional tumors. Other approaches (flexible sigmoidoscopy plus barium 
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enema or CT colonography) might be alternative options for patients with contraindication for 
colonoscopy (e.g., those with high comorbidities). For rectal cancer, because the treatment is 
based on the exact location of the tumor, the use of endoscopic ultrasonography (EUS) is 
necessary to for an accurate diagnosis and staging. A meta-analysis of the diagnostic accuracy of 
the EUS test shows that EUS is accurate for measuring T staging of rectal cancer.66 
CRC Staging  
According to the 2016 staging manual of the American Joint Committee on Cancer (AJCC),  
the staging for CRC is based on Tumor, Node, and Metastases (TNM) categories.67 T1 tumors 
involve the submucosa, T2 tumors involve muscularis propria, T3 tumors penetrate through 
muscularis propria, T4a tumors penetrate through the surface of visceral peritoneum, and T4b 
tumors invade or are adherent to other organs. The classification of lymph node involvement 
includes tumors with one positive lymph node (N1a), 2-3 positive lymph nodes (N1b), 4-6 lymph 
nodes (N2a) and ≥7 lymph nodes (N2b). Metastatic tumors include metastases to one organ 
(M1a), metastases to multiple distant organs (M1b) and peritoneal carcinomatosis with or 
without blood-borne metastases to visceral organs (M1c).  
Treatment 
Colon Cancer 
According to the NCCN guidelines, for non-metastatic colon cancer cases, the primary 
treatment depends on tumor resectability and the presence of colon obstruction by a tumor.67 
For a resectable non-obstructing tumor, colectomy with en bloc (i.e., cancer adherent to other 
organs) removal of regional lymph nodes is indicated. A resectable tumor that is blocking the 
colon is treated according to the patient’s condition, which might include a one-stage colectomy 
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with en block removal of regional nodes, resection with diversion, or diversion or stent and then 
colectomy. However, if the tumor is unresectable, systemic therapy (e.g., chemotherapy or 
biologics) is indicated with the objective of shrinking the tumor to make the tumor more operable. 
The three primary organs for metastasis for CRC are liver, lung and abdomen/peritoneal 
cavity. Tumors metastasized to the liver, the lung, or both are approached similarly. For those 
with resectable primary tumor and resectable metastases of liver or lung or both, patients are 
treated with staged or simultaneous resection. For patients with unresectable metastases, the 
systemic treatment is the only option even if the primary tumor is not obstructed. Among the 
most recommended systemic therapy are Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) and 
Folinic Acid-Fluorouracil-Capecitabine (FOLCape). Finally, patients with peritoneal metastases 
have shorter survival compared with those without peritoneal metastases, and the goal of the 
treatment of most cases is palliative rather than curative .67   
Rectal Cancer 
Rectal cancer patients are treated according to the clinical stage at diagnosis.68 Those 
diagnosed with early stage rectal cancer are primarily treated with surgical resection, usually done 
by local excision.67 However, patients who present with a locally advanced disease are more likely 
to receive neoadjuvant (i.e., before surgery) chemoradiotherapy followed by an appropriate 
surgical treatment. The primary goal of the chemoradiotherapy is to increase tumor resectability 
by downsizing the initial tumor. In contrasts to early-stage tumors, treatment of advanced stage 
tumors is through radical excision (i.e., excision of the rectum and mesorectum).  
There are several rectal cancer surgeries depending on tumor characteristics such as 
location and size. Among the surgical approaches that have been used are transanal excision, 
transanal endoscopic microsurgery, transanal minimal invasive surgery, transabdominal 
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resection, and sphincter-sparing surgery. In contrast to colon cancer, rectal cancer is usually 
treated with neoadjuvant therapy of chemoradiation. For early stages, chemoradiation is for 
those with T3-4 tumors that are node negative but where the tumor has penetrated the muscle 
wall. In stage-III, neoadjuvant chemoradiation is recommended for all tumors, and adjuvant 
chemotherapy is indicated in both stages II and III.    
Metastatic Colorectal Cancer 
Treatment   
Twenty percent of CRC patients are diagnosed with metastatic CRC.2 With the objective 
of planning the treatment, clinicians usually investigate whether the tumor is resectable and 
whether patients present with symptoms at the time of diagnosis.67 If the tumor is unresectable, 
patients are either treated with neoadjuvant therapy with the goal of making the tumor more 
operable or are treated with systemic therapy. However, if the tumor is resectable in both primary 
and metastatic sites, it is curable. Unfortunately, only 10%-20% of metastatic CRC patients are 
curable.67,69 
For curable tumors, there are three common approaches for the treatment of mCRC.70,71 
First, in the conventional staged approach, the primary tumor is resected first followed by 
chemotherapy for 3-6 months then the metastatic tumor is resected in a second surgery. The 
second approach, the liver-first approach, was introduced in 2008. This approach is limited to 
asymptomatic patients. It is a staged approach where the metastatic tumor is resected first 
followed by resection of the primary tumor. In this approach, neoadjuvant and adjuvant therapies 
are used as well. The third one is called the synchronous approach (simultaneous approach). In 
this approach, both the primary and metastatic tumors are resected during the same procedure.     
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 For incurable tumors, if patients present with a symptomatic tumor, primary tumor 
resection (PTR) is indicated. The current NCCN guidelines recommend PTR among metastatic CRC 
patients with symptomatic disease (e.g., obstruction, bleeding).67 However, for asymptomatic 
patients, there is no treatment consensus. Proponents of PTR among asymptomatic cases 
advocate surgical intervention because of its potential in preventing symptoms of the unresected 
primary tumor. However, some argue against doing so because the surgery can result in 
unecessary morbidity and mortality.72-74     
Effectiveness of Metastatic CRC Treatment 
Among asymptomatic patients, two studies used SEER data to investigate utilization of 
PTR.72,75 Cook et al. compared the characteristics and survival of metastatic CRC patients who 
underwent PTR with those treated with non-PTR between 1988 and 2000, while Hu et al. 
investigated the trends of PTR use from 1988 to 2010 when new systemic therapies 
(chemotherapeutic and targeted agents) were introduced to the market. Both studies found a 
reduction in PTR use over time, with a major decrease starting in 2001 at the time of introduction 
of new systemic therapies. During the same period, there were also increased survival rates 
among these patients, but it is unclear if this increase was due to higher use of systemic therapies 
or because surgeons are reluctant to operate on asymptomatic patients. Authors were not able 
to differentiate symptomatic patients form asymptomatic ones. Because the symptomatic status 
(symptomatic versus asymptomatic) is not captured in the data, the increased use of PTR might 
be due to selection bias. This bias could contribute to the decreased rate of PTR because it is 
unknown if the reduction was due to a decrease in PTR among asymptomatic patients or due to 
an increase in systemic therapy. 
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An additional study by Xu et al.76 using SEER data tried to circumvent the limitation of the 
previous two studies. They used the improved methodology of instrumental variable analysis to 
account for unmeasured confounding by linking Health Service Area (HSA) to the county where 
PTR took place. The authors reported better survival among the PTR group. They also looked at 
the impact of place of residence and found consistent improved overall and cancer-specific 
survival in the PTR group among patients in both metropolitan and non-metropolitan counties. 
Moreover, when Shapiro et al. investigated the same period using SEER data, they found gender, 
geographic region, insurance status, tumor location, tumor grade and Carcinoembryonic Antigen 
(CEA) level to be independent predictors of PTR. For instance, insured patients were 35% more 
likely to undergo PTR compared with uninsured patients.   
 A more recent review study74 investigated the differences in patient outcomes among 
metastatic patients who were treated with PTR followed by chemotherapy versus those with only 
primary chemotherapy. Overall, authors found better survival with PTR, although the two 
approaches were comparable. Specifically, among patients with primary chemotherapy, 3%-40% 
presented with complications of the unresectable primary tumor with onsets that varied between 
3-12 months. The most common complications included obstruction, perforation, hemorrhage, 
and pain. On the other hand, complications among patients who underwent PTR were wound 
infection, anastomotic leaks, urinary tract infection and ileus which required subsequent surgical 
intervention in 3%-11% of cases. In addition, postoperative mortality ranges from 2%-5% with a 
single study reporting an estimate of 29%. Lastly, factors that are more likely to predict overall 
survival among reviewed studies were the extent of hepatic involvement, Eastern Cooperative 
Oncology Group (ECOG) performance status ≥2, as well as metastatic dissemination to at least 
two distant sites compared to disease confined to one organ 
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Sphincter-Sparing Surgery 
Surgery Types and Effectiveness  
The two primary rectal cancer surgeries are Sphincter-Sparing Surgery (SSS) with 
intestinal continuity (also known as low anterior resection or LAR) and sphincter scarifying surgery 
with permanent colostomy (also known as abdominoperineal resection or APR).77 Not all rectal 
cancer patients are candidates for SSS. In general, the lower the tumor (i.e., the lower third of the 
rectum), the more difficult it is to resect while maintaining safe margins and therefore the less 
likely that SSS in indicated. Nonetheless, the ultimate decision is individualized. With a better 
definition of the clear safe margin for resection, the advancement in surgical technique and the 
development of staplers, patients with tumors at the lower third can be treated without 
sacrificing the sphincter.78,79  
Both SSS (LAR) and APR aim at reducing the local recurrence by ensuring tumor-free 
margins in the resected specimen. The most significant predictor of increased local recurrence 
and reduced survival is the tumor circumferential margin that is defined as the shortest distance 
between the mesorectal fascia and rectal tumor. Using histological samples, studies that 
compared LAR and APR showed higher positive margin from APR compared to LAR (SSS).80 Given 
the importance of sphincter-sparing, while maintaining bowel continuity, it is essential that 
patients receive SSS if indicated. Maintaining bowel continuity via SSS has a positive impact on 
patient's quality of life.81-83 However, not all patients who are candidates for SSS receive the 
surgery depending on tumor, patient and surgeon’s factors. 
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Current Knowledge about Colorectal Cancer in the Rural Health Literature 
Colorectal Cancer Screening by Geographic Location  
While CRC screening rates increased between 2000 and 2008, the increase in the 
prevalence of CRC screening among people with lower SES and those who live in rural areas have 
been relatively small.84,85 A study showed that rural residents are more likely to perceive that early 
detection of CRC is helpful compared with their urban counterparts; however, rural residents are 
less likely to receive screening for CRC.55 Using the national Behavioral Risk Factor Surveillance 
System (BRFSS) data, Cole et al. assessed CRC screening uptake by geographic location between 
1998 to 2005.86 They found that the more rural the place of residence was, the less likely an 
individual would get screened. The findings were also corroborated by other studies that used 
state-level data.87,88 Additionally, as shown in Figure 8 below, the northeast and some of the 
northern regions have the highest rates of CRC screening while the Midwest regions have the 
lowest rates.    
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Figure 8. Colorectal Cancer Screening (%), in Adults 50 Years and Older, BRFSS 20142 
Note: The estimates do not distinguish between examinations for screening and diagnosis. 
Screening tests included a fecal occult blood test within the past year or sigmoidoscopy within the 
past five years or colonoscopy within the past 10 years.  
Travel Time and Stage at Colorectal Cancer Diagnosis 
According to the National Household Travel Survey (NHTS), 41% of trips in the US traveled 
by rural residents for medical or dental services were longer than 30 minutes while only 25% of 
trips traveled by urban residents were longer than 30 minutes.89 Traveling is especially 
burdensome for cancer screening, with distance to a screening facility as a significant barrier for 
rural patients.88,90-98 This barrier is exacerbated in rural areas where primary care provider density 
is low, in particular among the younger adults and people with a lower SES.99 Rural populations 
overall are more likely to have unstaged cancers, and if staged disease, it tends to present as 
advanced CRC.100 
Rural-Urban Status and Colorectal Cancer Care and Outcomes 
Surgery is a significant part of CRC treatment since stages I-III and some metastatic 
patients are treated through surgery.67 Post-surgery, about 25% of patients who are operated on 
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need to get readmitted to the hospital due to factors that are not fully understood.101 Excessive 
readmissions following CRC surgery are estimated to cost $300 million annually.102 To contain 
these unnecessary costs, the Affordable Care Act includes the provision called the Hospital 
Readmission Reduction Program that penalizes hospitals for readmission after surgery.101,103 In 
2015, the penalty was 3% reduction in payments for all Medicare admissions during a given 
year.104  
Suspected factors that contribute to excess readmission can be classified into surgical and 
non-surgical. Surgery-related factors consist of preoperative (e.g., surgical approach, procedure-
urgency, comorbidities, obesity, the severity of illness, and indication), perioperative (e.g., 
operating time and stoma creation and immunosuppression use) and postoperative factors (e.g.. 
length of stay, complications, non-home discharge, blood transfusion, postoperative steroids). 
Non-surgical factors are geographic location, age, gender, race, SES and hospital’s patient 
volume.101,102  
Several studies have been conducted in the northern and southern part of the US. A multi-
institution study conducted in northern Minnesota, northwest Wisconsin, and the western 
portion of Michigan's Upper Peninsula, showed variations in CRC treatment between rural and 
urban patients and in general indicated that rural patients are at a disadvantage.105 Another study 
from the state of Georgia found no differences in surgical receipts by geographic location.106 
However, several studies lacked information about travel time to cancer care, hospital case 
volume, SES, patient’s comorbidities and complications.  
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Research Gaps 
Previous research on CRC shows that screening decreases incidence and mortality rates 
by detecting polyps or tumors at an early stage. Additionally, prior studies found that longer travel 
distance to screening facilities to be associated with late stage of diagnosis and delayed or no 
surgical treatment. Previous research was limited to self-reported surveys or focused on older 
adults (e.g., Medicare beneficiaries). Our study was designed to evaluate CRC screening uptake 
among a younger cohort of a privately insured population in a rural state; no previous work 
studied the characteristics of the younger CRC patients among the BCBSNE population. The 
younger working-age population included in this study are more likely than older population to 
have a busy schedule and less motivated to travel to colonoscopy facility to get screened and 
therefore more likely to be diagnosed with metastatic CRC. Therefore, this younger population is 
an ideal population.  
Additionally, no prior studies assessed the CRC surgery use and outcome among this 
population. Specifically, none of the previous studies assessed the association between rurality 
and 30-day hospital readmission among CRC patients who are privately-insured in a rural state. 
Only one study assessed 30-day hospital readmission using privately insured data but was not 
focused on CRC patients and, unlike our study, was not examining the impact of rurality on 
hospital readmission.  
Moreover, the association between rurality and the receipt of mCRC is not well 
characterized. For instance, four published studies evaluated the surgery uptake among patient 
with mCRC by geography. However, none of the studies assessed the impact of rurality. Instead, 
the studies either reported the geographic location of the SEER registry where cases have arisen 
(e.g., Northeast, South, etc.) or measured rurality at the county level. Further, none of these 
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studies assessed such relationship among the privately insured population. Although previous 
research found that in urban areas the odds of undergoing SSS is 1.4 times the odds of surgery in 
rural areas, it is not clear if such relationship sustains in a privately insured population who reside 
in a rural state.  
Furthermore, prior research shows that the majority of SSS were conducted in urban 
areas even after adjusting for hospital surgery volume.107,108 This suggests that other reasons 
could elucidate the differences between rural and urban population. For instance, higher income 
level and the availability of private insurance were associated with higher SSS uptake. It is unclear, 
however, if patient’s rurality status would have an impact on the receipt of SSS among the 
privately insured population in a rural state. To fill the gaps in the literature, this study had the 
following aims and related hypotheses:   
Specific Aims 
Aim1: To assess the impact of rural residence on CRC screening among 50-64 years old in 
a privately insured population.  
H1a: Colonoscopy rate is lower in the rural population compared to the urban population. 
H1b: FOBT screening rate is higher in the rural population compared to the urban 
population.  
H2: The urban population has higher PCP visits than the rural population. 
H3: Patients with a higher number of PCP visits are more likely to receive CRC screening. 
Aim2: To assess the impact of travel time on the stage of CRC at diagnosis among 50-64 
years old in a privately insured population.   
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H1: Shorter travel time to a colonoscopy facility is associated with a non-metastatic 
diagnosis of CRC.  
Aim3: To evaluate rural-urban differences in healthcare utilization among CRC patients.  
H1: Urban CRC patients who undergo surgery are more likely to have lower readmission 
and emergency department visits.  
H2: Among patients with metastatic CRC, the proportion who undergo surgery is higher 
among the urban population compared with the rural population.  
H3: Among rectal cancer patients, the proportion who undergo sphincter-preserving 
surgery is higher among the urban population compared with the rural population. 
Scope of the Study  
Our study is a retrospective cohort study conducted among privately insured adults 
residing in Nebraska. This unique population was rarely included in previous CRC studies. The 
study is limited to individuals who are 50-64 years old. It is also limited to the period from January 
2012 to June 2016. The Institutional Review Board at the University of Nebraska Medical Center 
approved the study. 
Summary    
CRC is the third most common cancer in the US and the third leading cause of cancer 
deaths. Although CRC can be prevented or detected at early stages when the treatment results in 
high survival rates, a large proportion of individuals are not screened. Specifically, the prevalence 
of CRC screening among the rural population and those with lower SES have been less than the 
urban population. Among the factors that contributed to lower screening is the distance to the 
screening or treatment facilities and this is especially burdensome for the rural patients. Some 
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previous studies found that longer travel distance to screening facilities to be associated with late 
stage of diagnosis and delayed or no surgical treatment. Additionally, hospital readmission rate 
has been shown to be higher among low volume centers which exist primarily in the rural areas. 
The study is significant because it is designed to characterize this privately-insured population for 
the first time. It is also designed to uncover differences between the rural and the urban 
populations in the receipt of CRC screening, the impact of travel time on stage at diagnosis, the 
differences in hospital readmission and the receipt of mCRC and SSS among a privately insured 
population. In addition to directing future research questions, our findings will have clinical and 
public health implications. For instance, if the rural population is less likely to receive indicated 
CRC surgery, this might reflect unawareness or disagreement with existing treatment guidelines. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
Definition and Characteristics of the Rural Population  
    There are 60 million adults in the US (20% of the US population) living in rural areas. 
109,110 Unlike urban communities, rural communities have lower population density, higher non-
working population such as elderly and children, more unemployed or underemployed who are 
less likely to be insured.109 Prior research showed that rural population and those with lower 
socioeconomic status were less likely to undergo screening, less likely to receive treatment and 
at an increased risk of death following CRC diagnosis.85-88,106,111-113 
The most widely used definitions of rural and urban populations are established by three 
government agencies: The U.S. Census Bureau, the Office of Management and Budget, and the 
Economic Research Service of the U.S. Department of Agriculture (USDA) (Table 1).114 The U.S. 
Census Bureau relies on total population or population density within a census tract to designate 
an area into rural or urban.109,115 There are three classes of areas:  An Urbanized Area (UA), an 
Urban Cluster (UC) and rural. UA has a population density of 50,000 or more people. The 
characteristic of the UA is that it has a core (at least one contiguous census block groups) with a 
total land area fewer than two square miles, might contain adjacent territory with at least 500 
people per square mile and include a population of at minimum 50,000 people. UC is similar to 
UA, but it contains a population less than 50,000 and at least 2,500 people. Any other territory, 
population, and housing units located outside the UA and UC areas are considered rural areas. 
Unlike the U.S. Census Bureau definition, the office of Management and Budget classifies 
counties as metropolitan and nonmetropolitan areas.109,115 Metropolitan areas are core counties 
with at least one urbanized area and outlying counties with economic ties to the core county as 
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measured by work commute. The outlying counties are considered part of the metropolitan area 
if 25% of workers commute to the urbanized area or if at least 25% of employment in the county 
consists of workers coming from the urbanized area. Furthermore, the nonmetropolitan counties 
are located outside the metropolitan areas and are divided into micropolitan (i.e., any nonmetro 
county with a cluster of the urban area more than or equals 10,000 people) and noncore counties.       
The USDA has two definitions that are measured at the county level: The Rural-Urban 
Continuum Code and the Urban Influence Code.116 The Rural-Urban continuum code classifies 
metropolitan counties by the population size of their metropolitan area and nonmetropolitan 
counties by the extent of urbanization and proximity to a metropolitan area. Counties are grouped 
based on their classification by the Office of Management and Budget (metro and nonmetro) then 
subdivided into three metropolitan and six nonmetropolitan classes. Unlike the Rural-Urban 
Continuum Code, the Urban Influence Code subdivides the metropolitan area into two 
metropolitan groups based on their size. It also subdivides the nonmetropolitan area into ten 
nonmetropolitan groups based on their proximity to the metropolitan area, and the 
nonmetropolitan-noncore counties into seven groups based on their proximity to metropolitan 
or micropolitan areas and if they have their town of more than 2,500 people.    
The Rural-Urban Commuting Areas (RUCAs) was developed by University of Washington 
with help from the Economic Research Service of the USDA.117 This classification uses the U.S. 
Census Bureau’s UA and UC definitions supplemented with information on work commute. The 
classification assigns metropolitan, micropolitan, small town and rural commuting areas with 
numbers between 1 and 10. These numbers are subdivided into 21 secondary codes based on 
commuting flows. Although the original RUCA classification was based on census tract, it uses the 
ZIP code as its geographic unit. 
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Table 1: Characteristics and Classifications of the Rural-Urban Areas114-116 
Classification  Geographic 
Unit Used  
Pros  Cons  
U.S. Census 
Bureau: Urban and 
Rural Areas 
Census Tract • Census is the 
smallest and most 
accurate 
geographic unit. 
• Reduces the 
problem of under-
bounding or 
overabounding 
that is associated 
with county-based 
classifications. 
• Definition based 
on census can 
be hard to 
implement 
because such 
small 
geographic unit 
is not commonly 
used by payers. 
• No stable across 
census years.   
U.S. Office of 
Management and 
Budget (OMB): 
Metropolitan and 
Nonmetropolitan 
areas      
County  • County boundaries 
represent political 
jurisdictions and 
considered stable 
over time.  
 
• County size 
differ across the 
U.S., and larger 
counties contain 
both rural and 
urban areas 
(over- and 
under-
bounding) 
Economic Research 
Service, USDA: The 
Urban Influence 
Code 
County • Because it 
differentiates 
counties with 
several small 
towns from those 
with one or two 
large towns for 
grouping 
nonmetropolitan 
counties, it is 
better than RUCA 
for suggesting a 
level of locally 
available services. 
Proximity to 
metropolitan areas 
indicates the 
degree of 
economic 
integration with 
• County size 
differs across 
the U.S., and 
larger counties 
contain both 
rural and urban 
areas. 
• Does not 
differentiate 
metropolitan 
counties as well 
as does RUCA. 
 
 
 
 
 
33 
 
metropolitan 
counties. 
Economic Research 
Service, USDA: The 
Rural-Urban 
Continuum Code 
County County boundaries 
represent political 
jurisdictions and 
considered stable over 
time. 
  
County size differs 
across the U.S., and 
larger counties contain 
both rural and urban 
areas. 
RUCA Census 
tract/ZIP code 
approximation 
• ZIP code areas are 
easy to implement 
with programs that 
are dependent on 
provider or 
beneficiary 
address. 
• Structuring of the 
codes allows for 
multiple levels of 
generalization- 
from 2 (rural-
urban) to 33.   
• ZIP codes are 
unstable and 
can change from 
year to year. 
• No stable across 
census years.   
 
 
No matter what definition one uses, the chosen definition will somehow over- or under-
represent urban or rural areas. The definition that dichotomizes areas (metropolitan and 
nonmetropolitan or rural and urban) will ignore any gradations in nonmetropolitan areas. For 
instance, the use of OMB definition will ignore proximity to metropolitan areas and thus 
underestimate the level of locally available services. However, the use of dichotomy is easier 
especially if the urban reflects the urbanest areas and the rural reflects the most rural areas.110 
According to Hart and colleagues,109 there are three points that researchers should 
consider when embarking on a project: the purpose of the study, the availability of data and the 
suitability and availability of definition. The primary purpose of our study is to measure travel time 
between members and providers. Because current study is not an interventional study (e.g., 
allocating resources or programs to areas that are not part of large urban or rural areas), using 
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RUCA as a dichotomy is appropriate. Regarding data availability, we have access to ZIP code 
provided by BCBSNE, which is more suitable for RUCA definition. The use of this definition is also 
consistent with previous studies, which make results comparable.86,87,118  
Roles of Primary Care Providers in Colorectal Cancer Screening  
The Institute of Medicine (IOM) defines primary care as “the provision of integrated, 
accessible health care services by clinicians who are accountable for addressing a large majority 
of personal health care needs, developing a sustained partnership with patients, and practicing in 
the context of family and community.”119 This definition emphasizes the important attributes of 
primary care such as the accessibility to health services, the sustained relationship between the 
healthcare provider and the patient and the integrated care to provide a referral to a specialist 
when needed. Primary care practice ensures the availability of a usual source of care, which is a 
well-established factor associated with an increased uptake of CRC screening.120-125    
Primary care providers (PCPs) include general practitioners or family medicine, internists 
and general pediatricians.125 A PCP is the patient's first contact with the healthcare system, and 
the preventive services are often initiated through primary care. In case of CRC prevention and 
control, the roles of a PCP include discussion and recommendation regarding screening, 
performing non-invasive screening (e.g., FOBT), and referring patients to specialists (e.g., 
gastroenterologists, general surgeons or colorectal surgeons) who can perform an endoscopic 
screening test.43 
Previous research demonstrates favorable CRC outcomes associated with PCP visits. For 
example, improved outcomes such as a lower incidence of late-stage CRC and a higher survival 
are proportional to the supply of PCPs.19,126-128 For each 10% increase in the supply of PCPs 
measured by the number of PCPs per 100,000 people, the odds of late stage diagnosis of CRC is 
35 
 
reduced by 5%.128 In particular, non-metropolitan areas with high level of PCPs supply is 
associated with less late-stage CRC.19 In contrast, each 10% increase in the supply of specialists 
such as gastroenterologists, general surgeons or colorectal surgeons is associated with 5% 
increase in late-stage CRC diagnosis. This could be because of the nature of the relationship 
between PCPs and patients, which tends to be longer and covers patients’ overall health, as 
opposed to the limited contact between specialists and patients.129  
 
 
Figure 9. Primary Care Physician Supply versus Demand, by State, 2025128 
Roles of Geography in Colorectal Cancer Screening Use 
There are many factors associated with the use of CRC screening including race, 
socioeconomic status, health insurance coverage, availability of a usual source of care, 
communication with provider, level of knowledge about CRC screening, rural residence and 
geographic access to screening facilities.85,130-132 An analysis of Behavioral Risk Factor Surveillance 
System (BRFSS) data indicated that rural residents are 17% less likely to be up-to-date on overall 
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CRC screening compared with urban residents.86 Moreover, compared to the urban and the rural 
residents, the remote rural (often termed as “frontier”) residents are the least likely to receive 
CRC screening.86 Limited use of CRC screening among the rural and the frontier community can 
be explained by the lack of access to screening facilities, the differences in individuals’ preference 
for the screening tests (e.g., individuals tend to prefer non-invasive tests such as FOBT) and the 
differences in provider’s recommendations (e.g., providers recommend colonoscopy, which is 
recommended once every 10 years, for individuals who are less likely to comply with the annual 
tests). 
 A recent study in Nebraska found similar disparities in CRC screening.113 Hughes and his 
colleagues used the Health Belief Model to elucidate factors that contribute to a lower CRC 
screening, especially in rural Nebraska.  The study found significant differences between the rural 
and the urban populations regarding their beliefs about CRC screening. For example, rural 
respondents perceived that they are less able to prevent themselves from getting CRC compared 
with the urban respondents. Also, there were significant differences concerning access to care, 
with rural residents tend to be less likely to identify a regular source of care. Having a usual source 
of care is a well-established reason for increased screening uptake.85 Interestingly, 35% of the 
rural residents reported that CRC screening cost too much while only 18% of the urban residents 
reported that the cost was too high. This view was held even though the majority of survey 
respondents were insured.  
One possible reason that rural residents are less likely to undergo CRC screening is the 
long distances they need to travel to the nearest colonoscopy facility as well as the lack of public 
transportation.87,88,113 On average, rural patients travel 30 minutes longer for medical or dental 
care compared with their urban counterparts.89 An analysis of the Utah BRFSS data shows that 
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among individuals at high risk of CRC (defined as those with a history of CRC, polyps or 
inflammatory bowel disease) individuals who traveled less than 10 minutes was significantly more 
likely to receive colonoscopy compared to those who traveled 20 minutes or longer.  It should be 
noted, however, that the study did not find a significant association between the median travel 
time to the nearest colonoscopy facility and CRC screening use.88  
Long-distance travel may be especially burdensome for CRC screening. Endoscopic 
screenings such as colonoscopy come with some logistical challenges such as the need for taking 
time off from work and the need for somebody to accompany the patient to the procedure. 
Although screening colonoscopy usually takes half an hour, as the patient needs to be sedated, 
the procedure requires the patient to take at least a day off from work or other usual activities. 
Also, because of sedation, the patient needs somebody to drive him or her back home after the 
procedure. Additionally, the unpleasant experience of bowel preparation before the procedure 
may be problematic for patients who live in the rural areas and need to travel long distance.   
Impact of Travel Time on Stage at Colorectal Cancer Diagnosis 
As mentioned earlier, an analysis of national BRFSS data and a survey study conducted in 
Nebraska suggest that rural residents are less likely to use CRC screening compared to urban 
residents and that longer travel time to a colonoscopy facility may be associated with less 
likelihood of colonoscopy screening.86,87,113 Furthermore, the literature suggests that rural 
residents are more likely to be diagnosed with late-stage CRC compared to urban residents. 
However, because of lack of research, the relationship between the travel time and the stage at 
diagnosis is not very well understood. To our knowledge, there are only two published population-
based studies that examined the stage at diagnosis.118,133  
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Charlton and colleagues used the Iowa SEER Cancer Registry that is linked with the 
Medicare claims database to assess both the impact of rural-urban status as well as travel time to 
colonoscopy facility on the stage of CRC diagnosis.118 In this Medicare sample, 69% were 
diagnosed with late-stage CRC. There was no significant association between rural-urban status 
or travel time and stage at diagnosis. Authors speculated that this insignificant finding might be 
due to the high accessibility to healthcare services in the state of Iowa since there is at least one 
hospital in each county. They also explained that travel time might become less of an issue when 
the PCP refers the patient to a gastroenterologist whom the patient is familiar with. Another 
possible explanation of the insignificant findings is that those at retirement age might not consider 
travel time as a barrier to CRC screening.  
The second study was conducted by Massarweh and colleagues using the National Cancer 
Data Base (NCDB).133 The authors examined factors associated with metastatic colon cancer 
diagnosis. In this study, where half of the patients were younger than 69 years old, authors found 
that 50% of their population were diagnosed with late-stage CRC. In the multivariate analysis, the 
authors reported a dose-response relationship between age and likelihood of metastatic colon 
cancer diagnosis where those younger than 60 years had the lowest odds of metastatic colon 
cancer diagnosis. They also showed that men were more likely to be diagnosed with metastatic 
CRC compared with women and those who were underinsured or with Medicare or Medicaid 
insurance were more likely to be diagnosed with metastatic CRC compared to those who were 
privately insured. Additionally, unlike the study from Iowa mentioned above, Massarweh et al. 
found a significant association between rural-urban status as well as travel distance and diagnosis 
of metastatic colon cancer. Those who lived in urban areas and those who lived in rural areas 
were 4% and 8% more likely to be diagnosed with metastatic colon cancer, respectively, compared 
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to those who live in metropolitan areas. Additionally, compared to those who traveled a short 
distance (<12.5 miles), those who traveled an intermediate distance (12.5-49.9 miles) and those 
who traveled a long distance (≥50 miles) were 18% less likely to be diagnosed with metastatic 
colon cancer. 
Rural-Urban Differences in Receipt of Colorectal Cancer Surgery among 
Patients with Metastatic Colorectal Cancer  
Twenty percent of CRC patients are diagnosed with metastatic CRC. While 10%-20% of 
metastatic CRC cases are curable2,67,69 CRC surgery among resectable metastatic CRC patients is a 
complex procedure and requires a multidisciplinary team to ensure safe and effective operation. 
Several prior studies found a positive association between the hospital surgery volume and clinical 
outcomes, which led many to advocate centralization of care (i.e., concentrate complex surgeries 
at high-volume hospitals). Toward that end and to ensure high-quality procedures, there has been 
an increase in the centralization of complex cancer surgery including ones for CRC.134 However, 
despite the benefit of centralization, travel barriers undermine the beneficial effect of 
centralization especially among the rural population,134-136 regardless of one’s insurance 
status.137,138  
There is a paucity of research that investigates the association between rural-urban status 
and surgery uptake among patients diagnosed with metastatic CRC. Four published studies 
assessed geographic location as a covariate in multivariable analyses.72,73,76,139 These studies found 
that while patients in the northeast are less likely to undergo PTR those who reside in the south 
are more likely to receive PTR. Further, 71.8% of those who live in the metro counties and 58.3% 
of those who live in the nonmetro counties have received PTR. However, these studies focused 
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on incurable metastatic CRC where the focus of the papers was on the PTR as opposed to 
synchronous or staged-resection of all metastatic tumors for curative purpose.  
Regional Variations in the CRC surgeries   
The provision of CRC surgeries varies by the geographic location and the availability of 
surgical centers with adequate surgery volume.134,135,140 Depending on the procedure type, the 
volume of surgery can widely vary by region which leads to the different distance traveled by 
patients to the treatment center. For instance, the distance traveled for esophageal cancer 
procedure ranges between 4.4 and 30.7 miles, for pancreatic cancer procedure between 3.0 and 
18.0 miles, for colon procedure between 1.9 and 9.3 miles and rectum procedure between 2.2 
and 9.9 miles. While the distance traveled to low-volume hospitals is usually shorter, the distance 
traveled to the high-volume hospitals is longer. For hospitals with very high volume, the distance 
traveled for esophageal cancer procedure ranges between 13.4 and 57.5 miles, for pancreatic 
cancer procedure between 9.6 and 43.3 miles, for colon procedure between 2.9 and 11.9 and 
rectum procedure between 4.8 and 24.5 miles. The differences in the provision of surgery 
according to the procedures’ volume resulted in regional variations depending on procedure type.            
The Regional Variation model classifies factors associated with regional variations into 
clinical and environmental factors.141  Examples of clinical factors include the physician’s decision 
to refer the patient to a surgeon or the surgeon’s belief about the indication for the surgery. 
Furthermore, examples of the environmental factors are technology diffusion, the supply of 
surgeons and financial incentives. Clinical factors reflect differences in disease incidence rates 
such that the higher the incidence of the disease the higher the observed volume for a given 
operation.134,135 Further, regional differences are a reflection of variations in the use of cancer 
detection methods such as screening, which subsequently leads to more or fewer surgeries.13 For 
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instance, an ecological study of prostate cancer found that Seattle, which had a higher screening 
rate than Connecticut, had a higher rate of prostatectomy use than Connecticut.142  
 Additionally, regional variations in CRC surgery is a result of differences in the availability 
of diagnostic testing. Since colonoscopy is the primary diagnostic test for CRC, both the availability 
of colonoscopy as well as the accessibility to a facility where colonoscopy is provided are essential 
to ensure timely tumor detection and, if indicated, surgical resection. Timely detection of tumors 
varies according to ones’ travel distance,133 disadvantaging rural residents.89  
Physician’s referral pattern is another reason that contributes to regional variations in 
CRC surgery. Depending on the type of surgery, physicians have different opinions on whether to 
operate and on the need to refer the patient to a high-volume hospital where the likelihood of a 
better outcome is higher.141 For example, variation in volume is measured using Systematic 
Component of Variation (SCV), where high SCV scores indicate large geographic variations and 
low SCV scores reflect low variations. Whereas prostatectomy has a very high score of 13.5, 
colectomy has low SCV score of 3.5 which reflects the consensus in clinical evidence that surgery 
is the treatment of choice for colon cancer patients.141 In other words, patient's preferences are 
less likely to influence treatment in colectomy but contribute significantly to prostatectomy 
(where the patient has to balance the psychological benefits of tumor removal and survival after 
surgery versus the risk of sexual dysfunction and permanent urinary incontinence from surgery).  
Unlike prostatectomy where there are significant variations between low and high-volume areas, 
colectomy is less likely to vary,143 and therefore referral is less likely to impact surgical uptake. 
The supply of surgeons also contributes to the regional variations in CRC surgery. Since 
1970, the supply of general surgeons has been steadily decreasing mainly because of the 
increased surgical sub-specialization, the aging of surgeons and the lack of training.144 For 
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example, during the past 25 years there was a 26% reduction in the number of general 
surgeons.145 Regions with the least supply is the rural areas where 56% of the rural counties have 
no general surgeons.146 Moreover, general surgeons lack advanced training, for example in 
laparoscopic and endoscopic techniques, which are predominant in rural hospitals.145   
Factors Associated with Sphincter-Sparing Surgery (SSS) 
There has been an increase utilization of SSS between the years 1988 (35.4%) and 2006 
(60.5%).107,108 Many factors determine who receive the SSS including patient, surgeon or hospital 
factors. In general, studies found that those who are male, of older age, Blacks, with Medicaid 
insurance or those who live in a lower-income ZIP code were less likely to receive the surgery. 
Additionally, high-volume hospitals located in urban areas were associated with a higher use of 
SSS compared to hospitals located in rural areas. 
Age is a significant predictor of SSS use where almost all previous studies found that the 
use of surgery significantly decreases with age.107,108,147 Among those who are younger than 60 
years of age, the likelihood of receiving the surgery is 21% higher compared with those who are 
60 years or older [OR: 1.21 (95% CI: 1.13, 1.29)].107,108 The differences in SSS use by age is due to 
the less aggressive treatment with aging (including any surgical intervention) and the lower 
likelihood of survival among elderly who underwent surgery.147 For instance, after adjustment for 
sex, race and tumor characteristics such as grade and stage, increased age is significantly 
associated with an increased likelihood of dying from rectal cancer. The magnitude of the 
likelihood of dying is higher among those 70 years and older [RR: 1.31 (95% CI: 1.25, 1.36)] 
compared with patients 69 years and younger [RR: 1.10 (95% CI: 1.05, 1.15)].147  
There are also racial disparities in the receipt of SSS, which have been reported in previous 
studies.107,148 After adjusting for stage and patients’ characteristics, a study using the SEER 
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database found that Blacks were 42% more likely to receive sphincter sacrificing procedure. 
Additionally, Ricciardi and colleagues noted a decline in SSS use among Blacks; the authors 
speculated that the decline might be due to geographic segregations where Blacks are less likely 
to see a physician who is sufficiently competent to operate.149  
While only 11% of patients who live in the rural areas receive SSS, the majority of patients 
who underwent SSS live in urban areas.108 In urban hospitals, where the volume of SSS is higher 
than rural hospitals, the odds of undergoing SSS is 1.4 times the odds of receiving surgery in rural 
hospitals [OR: 1.38 (95% CI: 1.26, 1.52)], even after adjusting for variations in SSS volumes 
between the rural and the urban hospitals, which indicates that other factors might explain 
variations between the rural and the urban areas.108 Other speculated factors include higher 
income level as well as the availability of private insurance, both of which are associated with the 
increased uptake of SSS.107 However, It is unknown if patients in rural areas will differ from those 
who live in urban areas in the rate of SSS uptake especially among a privately insured population.  
Factors Associated with Colorectal Cancer Surgical Outcomes 
Compared with the urban residents, the rural population tends to be older, with a lower 
income and with a lower level of education.101,150,151 These characteristics have been found to be 
associated with lower CRC surgery rates or poor outcomes.101,102,139,151 In addition to these 
differences, the rural population has more geographic barriers to cancer care especially 
sophisticated surgical therapy.152,153 This lower level of access to surgical care contributes to the 
worse surgical outcomes that have been experienced by the rural residents such as higher 
mortality, surgery-related complications and hospital readmission.150,154 For instance, the rural 
population is more likely to undergo cancer surgery as a result of a non-elective hospital 
admission.150   
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Many factors contribute to the increase in hospital readmission after colorectal surgery, 
including older age, male gender, Black race, lower income, lower education, being unmarried, 
lack of insurance, higher deprivation score, and lower SES. In general, previous studies of CRC 
surgeries found that the older the patients, the more likely that they were readmitted after the 
index surgery.155-159 Compared to the individuals who were 50 to 64 years of age, those who were 
65 and older were more likely to readmit. The odds of readmission increase proportionally with 
age.159,160 Those who were more likely to get readmitted within 30 days after CRC surgery tended 
to have increased odds of one-year mortality compared to those who were not, and this pattern 
in mortality increased with age.160,161 Moreover, mortality among older age groups (>80 years) 
compared with younger age group (<50 years) was higher in the rural hospitals [OR: 5.74 (95% CI: 
3.45, 9.54)] compared to the urban hospitals [OR: 4.32 (95% CI: 3.81, 4.90)]. 
In addition to the association between age and hospital readmission, gender and race 
were found to predict hospital readmission. Most studies found that male patients were more 
likely to be readmitted compared to female.102,155,159,161,162 For instance, Greenblatt et al. using 
SEER-Medicare database found that males were 20% more likely to be readmitted to the hospital 
within 30 days of CRC surgery, and 21% more likely to die within one year.161 One of the 
hypothesized reasons is that males tend to have longer hospital stay compared with females.155 
Additionally, Blacks were 17% more likely to be readmitted compared to Whites.155  
Moreover, clinical factors such as higher comorbidities, the use of immunosuppressant or 
steroids and obesity are associated with a higher likelihood of readmission.156,163-167  There are 
consistent findings between the association of comorbidity and readmission, a relationship which 
increases with the increased level of comorbidities. For instance, one study that used claims 
database reported a 13% increase in the hospital readmission rate as the severity of illness level 
45 
 
increased from 0 to 3, and a 29% increases in readmission as the severity of illness level increased 
from 0 to 4. Likewise, Schneider and colleagues found that those with Charlson Comorbidity Index 
(CCI) of 3 or higher were 27% more likely to be readmitted compared to those with a comorbidity 
score lower than 3.159 
Although readmission rates vary between 9%-25%, these variations reflect differences in 
perioperative factors. Specifically, readmission is higher among patients diagnosed with IBD, 
those admitted urgently, those with longer operation time, patients with complications and those 
discharged to nursing homes.  
Summary  
In this chapter, we defined the rural population, identified different classification systems 
for the rural and the urban populations including the pros and cons of each system and explained 
the characteristics of the rural population. We found that using RUCA system is more appropriate 
for the current study. We also defined PCPs and identified their role in the CRC screening process 
and the benefits (e.g., early detection of CRC or referral to specialists) associated with having a 
usual source of care. We then elucidated factors associated with CRC screening rates according 
to geography and stated that previous research found that rural residents are 17% less likely to 
be up to date in CRC screening. Some of the potential reasons for such lower screening rate is that 
rural patients are less likely to identify a usual source of care and more likely to travel long 
distances to receive care. Further, we evaluated the current literature on CRC stage at diagnosis 
between the rural and the urban populations and especially the effect of travel time. Although 
many studies have found that the rural population is less likely to get screened and more likely to 
get diagnosed at a later stage, the evidence is controversial about the impact of travel time on 
the stage of CRC diagnosis. These inconsistent findings are due to different study populations and 
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different sources of data. Moreover, there is a paucity of research about CRC treatment 
differences between the rural and the urban populations who are privately insured, especially the 
surgery use among those diagnosed with metastatic CRC and the SSS among rectal cancer 
patients.  
This study is designed to fill these gaps in the literature.  Unlike previous studies, our study 
characterizes the CRC screening among the privately insured population who live in a rural state. 
It also sheds light on the impact of travel time on CRC stage at diagnosis using working-age 
population, which we believe has never been studied. This population is unique because unlike 
other population (e.g., Medicare), the younger working population has busy schedules and are 
therefore less inclined to travel to colonoscopy facility to get screened and thus are more likely 
to present with metastatic CRC.   
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CHAPTER 3: RESEARCH METHODS 
Overview 
The current study is a retrospective cohort study using claims data from the state of 
Nebraska. The primary data used in this study were BlueCross BlueShield of Nebraska (BCBSNE), 
supplemented by information from the Rural-Urban Commuting Area Codes Data (RUCA), Health 
Professions Tracking Service (HPTS) and Google Map. The outcome variables were CRC screening 
use, stage at diagnosis of CRC, hospital readmission and emergency department visit following 
CRC surgery, CRC surgery use among patients diagnosed with metastatic CRC, and sphincter-
sparing surgery utilization among rectal cancer patients. The exposure variables included rural-
urban residence, travel time, and travel distance. The main analyses were X2-tests, Wald test, and 
multivariate logistic regressions.     
Data Sources 
 BlueCross BlueShield of Nebraska  
BCBSNE is the largest private health insurance company in Nebraska serving over 700,000 
people.168 The claims file, which contains 72,160,334 visits, includes services that occurred 
between January 1, 2012, and June 30, 2016, and were paid through September 15, 2016. These 
services consisted of verified claims from inpatient, professional and outpatient facilities. The data 
were limited to the providers and members who lived in Nebraska during the time the service was 
provided.  
The member file, which contains 920,227 visits, includes all members who were active 
between January 1, 2012, and June 30, 2016. The file also contains member’s demographic 
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information such as age, gender, member- and provider-5-digit ZIP codes. BCBSNE also captures 
members’ beginning and ending date of coverage. Diagnosis and procedural codes for the 
relevant inpatient, outpatient, and professional claims are all available as well.  
To assess sample representativeness, the proportion of the BCBS members residing in 
each regional health department district was compared to that of the Nebraska population 
(Appendix D). The proportions were similar except for Dakota County Health Department (0.35% 
for BCBS vs. 1.15% for state population) and for West Central District Health Department (0.23% 
for BCBS vs. 2.16% for state population).  
The Rural-Urban Commuting Area Codes Data  
RUCA is a publicly available data published by the University of Washington.169 It is a 
classification scheme that is based on census tract and uses the standard Bureau of Census 
Urbanized Area and Urban Cluster definition in combination with work commuting information 
to characterize all of the census tracts regarding their rural and urban status and their 
relationship.  
RUCA codes are based on the same concepts utilized by the Office of Management and 
Budget (OMB) to define county-level metropolitan and micropolitan areas. The RUCA codes used 
the same criteria by OMB by categorizing the U.S. census tracts using measures of population 
density, urbanization, and daily commuting.116 The latest RUCA codes are based on the 2010 
decennial census and the 2006-2010 American Community Survey.  
There are ten primary and 21 secondary codes in RUCA. The primary codes consist of 
whole numbers (1-10) that represent metropolitan, micropolitan, small town, and rural 
commuting areas based on size and direction of largest commuting flows. The secondary codes 
subdivide the ten codes based on secondary commuting flows. Therefore, the classification 
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satisfies various needs by allowing users to choose their preferred definitions. For the current 
study, we used “Categorization C” to dichotomize the area of residence into rural and urban.  We 
used this categorization because other categorization would break the sample into subgroups that 
are too small.    
Google Maps Data 
Commercial websites such as Google offer accurate driving directions between places. 
Open-source programming language (i.e., developed by the referenced authors) that is available 
on SAS was used to make repeated calls to Google to obtain travel time information for any 
number of locations.170 Subsequently, the program was tested by the same authors using a 
nationally representative sample that covers 66,000 locations in the fifty states, the District of 
Columbia and Puerto Rico.171 The authors suggest that the SAS code could change to reflect the 
occasional changes in Google web site structure.  For example, if Google map changes its URL, the 
same change must be reflected in the FILENAME statement in SAS (Please see below for 
FILENAME method).  
In this study, we utilized publicly available Google Maps to calculate travel time as well as 
travel distance. We calculated travel time by measuring time in minutes between the geographic 
centroid of each member ZIP code of residence and the provider ZIP code at the time of service. 
Travel time calculations were made via repeated calls to the Google Maps Web page using SAS 
FILENAME URL method in SAS.171 The method has a high correlation with straight-line distance 
(r2=0.96) but with superior travel time estimate. When both members and providers had the same 
ZIP code (i.e., artificial zero bias), we conducted a sensitivity analysis to assess the impact of small 
variations of travel time (1-, 10-, and 20-minutes) on the metastatic stage at diagnosis.172 There 
were no changes in the proportion of metastatic CRC with the changes in travel time. 
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Health Professions Tracking Service (HPTS) 
The HPTS is Nebraska’s healthcare workforce monitoring systems since 1995.173 It collects 
information about health care providers practicing in Nebraska. The collected information 
includes profession, license type, primary specialty, training, expertise, languages spoken fluently, 
retirement plans, practice setting and arrangements for all practice site locations, the ZIP code 
and county of practice location. The list of professionals is updated periodically to reflect active 
practitioners in Nebraska.  
We used HPTS data to measure access to PCP. The measure is based on the provider-to-
population ratio and calculated by dividing the total number of actively practicing PCPs (i.e., 
medical or osteopathic physician who specializes in general practice, internal medicine or family 
practice) in each ZIP code by the total population of each ZIP code.110  
Study Samples  
There were two samples for Aim 1 (Sample-1 and Sample-2; Figures 10 and 11 below). 
The objective of using Sample-1 was to assess the annual use of FOBT or colonoscopy. The 
eligibility criteria for Sample-1 were BCBSNE members aged 50-64 years old during the year and 
with average-risk CRC. The cut-off age of 50 was used because this age is considered the average-
risk age for the development of CRC according to the USPSTF guideline.48 We excluded members 
who were 65 years and older because of their supplemental Medicare insurance. That is, these 
members have additional coverage through Medicare, and therefore some of their procedures 
are not captured in BCBSNE. We also excluded members with high risk of development of CRC 
during each year. 
As shown in Figure 10, we first identified the 765,868 members in BCBSNE who have any 
membership coverage between January 1st, 2012 and June 30th, 2016. We excluded members who 
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have duplicate enrollment records, overlap in the coverage periods or gaps in enrollment more 
than 31 days.174 These exclusions, though not part of eligibility criteria, were necessary to prepare 
data for final analysis. Among the 688,299 members with no lapse in coverage of more than 31 
days, we excluded 546,703 individuals who were outside of the age group of interest. Next, we 
excluded 36,448 high-risk members defined as members who had a personal history of CRC or 
adenomatous polyps or a personal history of inflammatory bowel disease. We were unable to 
exclude members with a family history of CRC or polyps or a known family history of a hereditary 
CRC syndrome such as familial adenomatous polyps or Lynch syndrome because these members 
are not captured in the data. A total of 105,148 members met the eligibility criteria for Aim 1 
Sample-1. Finally, we looked at every single year and identified members who have coverage for 
the entire year. Some members have coverage for more than one year.   
Moreover, the objective of using Sample-2 was to assess the association between rural-
urban status and the CRC screening use (Figure 11). We limited our cohort to members who were 
continuously-enrolled during the 2013-2015 period (319,245). We did so to ensure the 
temporality between the covariates and the outcome. That is, we want to ensure that the CRC 
screening tests occur after PCP visits. We further limited the sample to the age groups 50-64 years 
old and members with average risk CRC (78,891). Finally, we excluded members with no records 
(the only available variables for these members was their IDs). A total of 58,774 members met the 
eligibility criteria for Aim 1 Sample-2. 
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Figure 10. Aim 1 Sample-1 Selection Flow Chart  
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Figure 11. Aim 1 Sample-2 Selection Flow Chart  
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For Aim 2, the study sample consisted of members aged 50-64 years old with no history 
of cancer (Figure 12). Out of the 688,299 members, we excluded a total of 546,703 members who 
were younger than 50 years because they are not recommended for screening. We excluded 
members who were older than 65 years of age because the BCBSNE data likely did not contain 
claims for all their health services that may have been covered under Medicare. We also excluded 
140,771 people with no diagnosis of CRC. Further, we excluded 149 members with no inpatient 
claims or fewer than two outpatient claims for CRC because they did not meet our CRC diagnosis 
definition. We also limited our sample to those with 6-month continuous enrollment before CRC 
diagnosis and those with no prior cancers. We chose the six months cut-off time to ensure that 
the identified cases are incident and not prevalent cases.175  
We conducted sensitivity analysis, that is guided by publications from Setoguchi and 
colleagues,175 Song and colleagues,176 Paramore and colleagues,177 and Rao and colleagues.178 
These definitions have high agreement with cases reported in the cancer registry in the date of 
the first diagnosis. All definitions reported by the authors resulted in high specificity and good 
sensitivity for identifying incident cases. Given that CRC is a rare outcome and in order to improve 
statistical efficiency, we chose the definition that resulted in high sensitivity. Accordingly, we 
assumed that those who met the definition of at least one inpatient or at least two outpatient 
claims of CRC and who have no CRC cancer within six months prior to first CRC diagnosis to be 
diagnosed with CRC (see Appendix C). 
 For the travel time analysis, we limited our analysis to members who had colonoscopy 
claims during the four months prior to CRC diagnosis. We conducted a sensitivity analysis to assess 
the impact of different continuous enrollment periods (4, 6, 9, 12, 18 and 24 months) on 
percentages of colonoscopy use and on whether the identified cases were incident not prevalent 
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cases. A total of 204 members met the eligibility criteria and used in the calculation of travel time 
(Figure 12). 
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Figure 12. Aim 2 Eligibility Criteria 
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For Aim 3, Hypotheses 1-3, the study sample consisted of CRC patients between the ages 
of 19-65 years old (Figures 13-15). Of the 688,299 members, we excluded the following: 255,934 
who were younger than 19 years or 65 years or older, and 431,290 with no CRC diagnosis. For 
Hypothesis 1, the following additional exclusion criteria were applied: no inpatient claims or fewer 
than two outpatient claims or those who were not continuously enrolled for six months before 
CRC diagnosis (n=147), no surgery claims (n=284), and no admission or discharge dates (n=72). A 
total of 315 members met the eligibility criteria (Figure 13). 
For Hypothesis 2, the following additional criteria were applied: no inpatient claims or 
fewer than two outpatient claims or those who were not continuously enrolled for 6 months prior 
to CRC diagnosis (n=147), no metastatic stage at diagnosis for CRC (n=487), no inpatient claim or 
fewer than two outpatient claims for mCRC (n=23), and diagnosed with other primary cancers 
(n=92). A total of 69 members met the eligibility criteria (Figure 14). 
For Hypothesis 3, the following additional criteria were applied:  no diagnosis of rectal 
cancer (n=431,863), diagnosed with anal cancer (n=121), no inpatient claims or fewer than two 
outpatient claims (n=136) and no rectal cancer surgery (n=155).  A total of 90 members met the 
eligibility criteria (Figure 15).   
 
 
 
 
 
58 
 
 
Figure 13. Aim 3-Hypothesis 1 Eligibility Criteria 
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 Figure 14. Aim 3-Hypothesis 2 Eligibility Criteria 
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Figure 15. Aim 3-Hypothesis 3 Eligibility Criteria 
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Key Variables and Measures 
Table 1 summarizes select key variables and measures. In the following, assumptions and 
definitions for the key variables and measures are described.  
Coverage Dates, Service Dates and Age at Diagnosis 
To identify the coverage period, variables called “beginning date of coverage” and 
“ending date of coverage” were identified from the BCBSNE enrollment files. These variables were 
used during the data preparation step when we removed duplicate records and corrected the 
coverage periods (e.g., by removing overlap coverage). For beginning and ending dates of service, 
the first and last dates of service by a recognized medical practitioner during the study period 
(1/1/12-6/30/16) were used to identify services related to the research questions (e.g., CRC 
diagnosis). Age at diagnosis was identified using the age when the first CRC diagnosis was reported 
within the six months continuous enrollment provided.  
CRC Risk, Diagnosis and Staging  
Claims data were used to identify individuals who had ICD codes for the malignant 
neoplasm of colon or rectum (excluding anal cancer). For the specific codes used, see Appendix 
B.  Individuals were considered to be diagnosed with CRC if they had at least one inpatient claim 
or at least two outpatient claims for CRC diagnosis during the study period (2012-2016).  ICD codes 
are based on codes used in a similar study by several authors118,133,175 (Appendix B3). Note that 
given that the BCBSNE did not provide CRC diagnosis variable, we had to make assumptions to 
develop an operational definition of CRC diagnosis. These assumptions were guided by 
publications from Setoguchi and colleagues,175 Song and colleagues,176 Paramore and 
colleagues,177 and Rao and colleagues.178 For instance, we applied the definitions suggested by 
Setoguchi and colleagues to define incident CRC in administrative data. These definitions have 
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high agreement with cases reported in cancer registry in the date of the first diagnosis. All 
definitions reported by the authors resulted in high specificity (99.62%-98.51%) and good 
sensitivity (67.25%-88.02%) for identifying incident cases. Given that CRC is a rare outcome and 
in order to improve statistical efficiency, we chose the definition that resulted in a high sensitivity. 
Accordingly, we assumed that those who met the definition of at least one inpatient or at least 
two outpatient claims of CRC to be diagnosed with CRC.  Based on a study by Gupta et al. who 
used claims data to study CRC, high-risk groups was operationally defined as those who have 
previous CRC diagnosis, polyps diagnosis or inflammatory bowel disease.179  
Given that BCBSNE does not have a variable to identify stage at diagnosis, we reviewed 
the literature and consulted with the surgeon about measuring CRC stage at diagnosis. Several 
publications have used secondary malignant CRC as a surrogate for metastatic CRC176,177 and 
metastatic breast cancer.178 Thus, we assumed that patients who were diagnosed with secondary 
metastatic neoplasm, according to Appendix B4, would have been diagnosed with metastatic CRC.  
In this study, the CRC staging was dichotomized into metastases versus non-metastatic CRC. 
Metastasis was defined as the occurrence of at least one inpatient claim or at least two outpatient 
claims for metastatic CRC codes (Appendix C) within 30 days before CRC diagnosis or any time 
after CRC diagnosis. These codes have also been used elsewhere.177  
CRC Screening  
In order to define the purpose of colonoscopy (i.e., Screening versus Diagnostic or 
Surveillance), we identified the pertinent ICD and CPT codes. Members were classified as having 
a diagnostic colonoscopy if they received claims indicating CRC symptoms such as blood in stool, 
rectal bleeding or abdominal pain four months prior to colonoscopy (see Appendix X for specific 
codes used). To be classified as having surveillance colonoscopy, members should not have claims 
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associated with potential CRC symptoms but should have diagnoses indicating a history of a 
condition that merits more frequent CRC surveillance such as polyps or IBD. Members who did 
not meet the diagnostic or surveillance criteria above were classified as having a screening 
colonoscopy (see Appendix B1, B2, and B5 for specific codes used).  
We assessed members who received colonoscopy within four months prior- or two weeks 
post-diagnosis of CRC to determine if the purpose of colonoscopy was screening, surveillance or 
diagnostic (Appendix C6). We conducted sensitivity analysis for periods between three and six 
months prior- and between two weeks and six months post-diagnosis. But this sensitivity analysis 
resulted in fewer additional colposcopies identified. For instance, restricting to six months of 
continuous enrollment before diagnosis resulted in 210 cases, four months resulted in 204 cases 
and three months resulted in 200 cases. Likewise, restricting continuous enrollment for a post-
diagnosis period of 14 days resulted in 22 cases, 30 days to 25 cases, 60 or 90 days to 31 cases, 
120 days to 35 cases and 180 days to 44 cases. We decided to choose four months prior- or two 
weeks post-diagnosis of CRC because of the fewer cases identified by extending the time. 
CRC Surgery and Readmission 
Receipt of CRC surgery was defined as the endoscopic removal of polyps (polypectomy), 
local excision, resection of the primary tumor with or without stoma creation among patients with 
six months continuous enrollment before CRC diagnosis and six months continuous enrollment 
after CRC diagnosis. The one year of continuous enrollment was chosen to ensure that we are not 
missing surgeries conducted after systemic therapy according to guidelines (i.e., surgery after 
neoadjuvant therapy).67 For the codes used to identify surgeries, see Appendix B7 and B8. These 
codes were used after consultation with the surgeon and after meeting with the trained coder. 
Additionally, these codes were guided by previous publications.101,102,155,161,180 After applying these 
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codes, we found that the rate of CRC surgery is lower than what has been reported in the 
literature.101 To fully understand the lower rates of CRC surgery, we conducted a sensitivity 
analysis. Please refer to Appendix C for the detailed explanation and results of the sensitivity 
analysis.  
Finally, the 30-day readmission was defined as the number of patients who were 
discharged from hospital and readmitted within 30 days divided by the number of all people who 
were discharged. The same definition has been used in a previous publication.181 Operationally, 
we used the inpatient records and the two variables created by BCBSNE (admission date and 
discharge date) to measure hospital readmission. For the codes used to determine the 
readmission, see Appendix B.   
Classification of Rural-Urban Status  
According to RUCA developer,117 a total of 33 codes can be used to categorize geographic 
population. A researcher can collapse these codes into categories that fit his or her research 
objectives. For instance, one can choose categories from the table below. Consistent with the 
relevant literature, we used Categorization ‘C.’ Since the current study is limited to a sample of 
Nebraska residents, we used RUCA Nebraska file. 
Measurement of Travel Time to Screening Facility  
For the measurement of travel distance and travel time, we used Google Maps as well as 
BSBSNE’s provided member’s 5- digit ZIP codes and providers’ 5- digit ZIP codes. Many previous 
studies defined distance as the straight-line distance between locations using coordinates or 
latitude and longitude. Although the straight-line distance is useful,171 a greater precision can be 
achieved using actual road distance when the driving distance is estimated using Google Maps.      
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Using the centroid of ZIP code, we calculated the travel time between members and 
providers. Accordingly, travel time is defined as the time in minutes between the ZIP codes’ 
centroid for participants and the ZIP codes’ centroid for providers. There are three main steps for 
the calculation of travel distance: 1) identification of distances between a single ZIP code and all 
ZIP codes in Nebraska,170 2) combining all calculated distances, and 3) merging distance for the 
study sample.  
To operationalize travel time, we used the date of the first claim of index colonoscopy to 
identify both participants as well as provider addresses. We measured travel time as a continuous 
variable and reported the mean and median. When both members and providers have the same 
ZIP code, we conducted a sensitivity analysis to assess the impact of small variations of travel time 
(1-, 10-, and 20-minutes) on the metastatic stage at diagnosis. 
PCP Access and Preventive Service Use  
The PCP access was defined as the provider-to-population ratios which highlight gaps in 
service availability and delivery.110 It was calculated by dividing the total number of actively 
practicing PCPs in each ZIP code by the total population of each ZIP code. 
Preventive service use was defined as any health services such as checkups or counseling 
to prevent illness or to detect illness at an early stage when treatment is more viable.182 For the 
codes used for to identify preventive services, see Appendix B6. These codes have been used in 
previous study.183 
Primary Care Physician Visits 
Primary care physician visits were measured using the number of visit in a calendar year 
to a general practitioner, an internist or family practitioner. For Sample-1 of Aim 1, we looked at 
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the number of PCP visits during a calendar year. For Sample-2 of Aim 1, we looked at the number 
of visits during a two-year period (2013-2014). 
Enhanced Charlson Comorbidity Index 
Enhanced Charlson Comorbidity Index was developed by Charlson et al. to determine the 
burden of disease and case mix.184 Researchers use the index to account for comorbidities in the 
regression models. To apply the index to administrative data, other authors modified the 
comorbidity index and validated its use.185,186 In 2011, Quan et al. updated the index that was 
validated for use in administrative data by adjusting the weights of comorbidities.187  
 
Table 2. Description of select key variable and measures 
Variable / Measure Data Source and Operational Definition  
Beginning date of coverage  BCBS enrollment file. The first date of BCBSNE coverage. 
Ending date of coverage  BCBS enrollment file. The last date of BCBSNE coverage. 
Beginning date of service BCBS enrollment file. The first date of service by a recognized medical 
practitioner during the data period 1/1/12-6/30/16. The calendar 
year of service derived from date of service. 
Ending date of service BCBS enrollment file. The last date of service by a recognized medical 
practitioner during the data period 1/1/12-6/30/16. The calendar 
year of service derived from the end date of service. 
Age at diagnosis  BCBS enrollment file. Member’s age at the time of CRC diagnosis 
Receipt of FOBT BCBS claims file. Having at least one paid claim for FOBT conducted 
during the specified calendar year.  
Receipt of screening 
colonoscopy 
BCBS claims file. Having at least one paid claim for non-diagnostic and 
non-surveillance colonoscopy conducted during the calendar year. 
Receipt of diagnostic 
colonoscopy 
BCBS claims file. Having at least one paid claim for diagnostic 
colonoscopy (i.e., symptoms such as rectal bleeding) conducted during 
the calendar year. 
Receipt of surveillance 
colonoscopy 
BCBS claims file. Having at least one paid claim for surveillance 
colonoscopy (i.e., among high-risk individuals with a history of CRC, 
polyps or IBD) conducted during the calendar year. 
High-risk individuals BCBS claims file. Having a history of CRC, polyps or IBD. 
CRC diagnosis  BCBS claims file. Having at least one inpatient or at least two 
outpatient claims of CRC diagnosis during the specified continuous 
enrollment. 
Metastatic stage of CRC BCBS claims file. Having at least one inpatient or at least two 
outpatient claims of metastatic CRC diagnosis within 30 days before 
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CRC diagnosis or any time after CRC diagnosis during the specified 
continuous enrollment.  
Receipt of CRC surgery  BSBS claims file. Having at least one claim for CRC surgery during 
specified continuous enrollment with BCBSNE. 
ER visit Emergency department visit within 30 days after CRC surgery. 
30-day readmission The number of patients who were discharged from hospital and 
readmitted within 30 days divided by the number of all people who 
were discharged.  
Rural-urban status of 
member’s residence 
BCBS enrollment file. Based on RUCA classification system, individuals 
who lived within the ZIP codes that were designated as a rural area by 
RUCA were classified as rural residents, and the remaining were 
classified as urban residents.  
Travel time to receive 
health care 
BCBS denominator and claims files. A straight-line travel time 
between the geographic centroid of member ZIP code and the 
provider ZIP code at the time of service calculated by Google Map.  
PCP access  
 
2016 HPTS data and 2010 US Census data. The number of actively 
practicing PCPs per population in a given zip code.   
PCP visits Primary care physician visits are computed using the number of visit 
in a calendar year to a general practitioner, an internist or family 
practitioner. For Sample-2 of Aim 1, we looked at the number of visits 
during a two years period (2013-2014).  
Preventive service use  Preventive services are any health services such as checkups or 
counseling to prevent illness or to detect illness at an early stage 
when treatment is more viable. 
Enhanced Charlson 
comorbidity index  
A method developed by Charlson et al. and is used to determine 
comorbidities or the burden of disease and case mix. Quan et al. 
updated the index that is used in administrative data by adjusting the 
weights for comorbidities. For Aim 1, we included cancer diagnosis as 
part of the measurements of CCI, however; we excluded cancer 
diagnosis from the calculation in Aim 3 where all study populations 
were diagnosed with CRC. 
 
Missing Data 
For Aim 1, there were six observations with missing value for the rural-urban status. For 
Aim 2, the only missing variable was “access to primary care physician” (26% missing). We did not 
use access to PCP in our analyses. This variable was created using the HPTS data because it is not 
available in the BCBSNE data. To circumvent the problem of missing data, we imputed the value 
of the missing variable. Because there was an association between other covariates and stage at 
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diagnosis, we assumed that “access to primary care physician” is Missing At Random (MAR). 
Therefore, multiple imputations using the SAS procedure PROC MI was used. The imputation 
consisted of three phases: the imputation phase where we ran a total of 10 imputations; the 
analysis phase where logistic regression was used to calculate parameter estimates and odds 
ratios; and the pooling phase where the parameter estimates from analysis phases were pooled. 
Finally, for Aim 3, there were no missing variables. 
Statistical Analyses 
We used SAS statistical software version 9.4 (SAS Institute Inc. Cary, NC) to conduct all 
analyses. All tests were 2-tailed with α level of 0.05.  
Aim 1 
The first aim was to assess the impact of rural residence on CRC screening. The first part 
of the analysis was to estimate the annual prevalence rates for FOBT and colonoscopy. The 
numerator was the number of members with at least one paid claim for the specified screening 
test during the specific year.  The denominator was the number of members eligible for screening 
during the specific year. To compare the rates between urban and rural members, we used X2-
test. The same test was used to assess the CRC screening use across years as displayed in Figure1.  
The second part of the analysis was to assess the association between rural-urban status 
and FOBT or colonoscopy use. We estimated the unadjusted odds ratios using univariate logistic 
regression. The variables used in the univariate models are age, gender, rural-urban status, PCP 
visit in 2013-2014 and CCI. Predictor variables with p-value <0.25 were included in the 
multivariate model. We assessed if the association between rural-urban status and the use of 
FOBT was modified by assessing the interaction. We found that there were interactions between 
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rural-urban status and age, gender and PCP visits. Likewise, there was an interaction between 
rural-urban status and age when we assessed the colonoscopy use. We reported the stratified 
results by each of the effect modifiers.   
Aim 2 
We used Wilcoxon rank-sum tests for continuous variables and X2-tests for categorical 
variables. We also used univariate analysis to compare metastatic versus non-metastatic CRC 
diagnosis using univariate logistic regression. In the univariate analysis, we made comparisons by 
age, gender, rural-urban status, use of colonoscopy within four months prior to CRC diagnosis and 
travel time. Wald tests were used to assess predictors’ significance. We checked interaction 
between travel time and age, gender, rural-urban status, use of colonoscopy within four months 
prior to CRC diagnosis and there was no interaction. 
We used the fractional polynomial method (PROC LOESS) to examine any non-linear 
relationship between the log odds of metastatic diagnosis and continuous variables. We inspected 
the curves of the predictors against the dichotomous response and used the likelihood ratio test 
for improvement in fit against the assumed linear relationship. Lastly, we conducted a 
multivariate logistic regression analysis to assess the relationship between travel time and 
metastatic CRC diagnosis adjusting for all variables.  Univariate logistic regression analyses were 
conducted to assess the association between the predictor variables (age, gender, rural-urban 
status, use of preventive services, colonoscopy type, and PCP access) and the metastatic CRC. 
Predictor variables with p-value <0.25 were included in the multivariate logistic model. 
Multivariate logistic regression was built to adjust for the confounding variables using the step-
wise method. There was no interaction between travel-time and predictors. We used PROC 
LOGISTIC in SAS statistical software. 
70 
 
Aim 3  
We used descriptive analysis to compare the demographic and clinical characteristics 
between the rural and the urban populations. For the significance tests, we used X2-test for 
categorical variables and t-test for continuous variables. Hospital readmission was defined as re-
hospitalization within 30 days of the index hospitalization. Patients with any hospitalization after 
the index surgery were identified using inpatient CRC claims. These patients were then classified 
according to their time of inpatient visits after the index surgery into hospitalization within 30 
days versus more than 30 days.  For the univariate analysis, we used logistic regression model to 
compare the readmitted patients versus the non-readmitted, and patients who received surgery 
from those who did not receive the surgery among all variables; Wald tests were the test of 
significance. We also estimated the unadjusted odds ratios using univariate logistic regression 
models for the rural residence among those readmitted versus none and those received surgery 
versus no surgery. Readmission and surgery status were estimated using multivariate logistic 
regression.   
Univariate analyses were performed between hospital readmission and clinical and 
demographic variables. Logistic regression was conducted to assess the association between 
rural-urban status and hospital readmission after adjustment for the following independent 
variables: surgery approach, the presence of intestinal obstruction or perforation and CCI. These 
independent variables were based on previous knowledge of the association between rural-urban 
status and readmission or were with p-value <0.25. The variables include age, gender, travel-time, 
LOS, tumor location, site of surgery and stoma creation. There were no interactions between 
rural-urban status and independent variables. 
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Receipt of surgery among metastatic CRC patients was calculated by measuring the 
proportion of CRC patients who were in the rural and the urban population and comparing them 
for the receipt of surgery. Receipt of rectal surgery is measured by calculating the proportion of 
rectal cancer patients who are in the rural and urban areas and comparing them for the receipt 
of surgery. For Hypothesis 2 (the relationship between rural-urban status and the use of surgery 
among patient diagnosed with metastatic CRC), univariate analyses were conducted to assess the 
relationship between the predictor variables and the use of surgery among patients diagnosed 
with metastatic CRC. These variables are age, gender, rural-urban status, CCI, travel-time, primary 
tumor site, site of metastasis, number of metastatic sites and access to PCP services. Predictor 
variables with p-value <0.25 were included in the multivariate model. Multivariate logistic 
regressions were built to adjust for the confounding variables using the step-wise method. We 
also assessed the interaction between rural-urban status and all predictors and found no 
interaction.  For Hypothesis 3 (the relationship between rural-urban status and the use of surgery 
among patient diagnosed with rectal cancer), univariate analyses were assessed between rural-
urban status and the use of SSS in patients diagnosed with rectal cancer. 
Sample Size Calculation 
Because some of the analyses were underpowered, a post hoc sample size calculation 
was conducted (Table 3). The travel time sample size calculation was based on findings from the 
current study:  the median travel time of 19 minutes, and those who live closer to the facility to 
be less likely to be diagnosed with metastatic CRC (15%). The estimated sample size was 
calculated using the PROC POWER in SAS. It was found that for a comparison of two independent 
binomial proportions using Pearson's X2-test statistic with X2 approximation with a two-sided 
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significance level of 0.05, a sample size of 175 per group has an approximate power of 0.79 when 
the proportions are 0.15 and 0.27.  
   Table 3: Power Analysis 
Power analysis for varying proportions of subjects who live >19 minutes from 
colonoscopy facility, assuming 0.15 metastatic CRC in subjects who live ≤19 minutes, 
α=0.05  
Power  Proportion of metastatic CRC in 
subjects live >19 minutes of 
colonoscopy facility  
Sample size per group  
0.23 0.20 173 
0.31 0.21 176 
0.40 0.22 179 
0.48 0.23 176 
0.56 0.24 173 
0.65 0.25 176 
0.72 0.26 174 
0.80 0.27 175 
0.84 0.28 173 
Summary 
The current study is a retrospective cohort study of a privately insured population from 
Nebraska. The overall study population comprised of members who met the eligibility criteria as 
described in Figures 10-15 between the years of 2012 and 2016. The main exposures were rural-
urban status and travel time. The main outcomes were screening use, stage at CRC diagnosis, 
hospital readmission and emergency department visits, surgery use among patients diagnosed 
with metastatic CRC and sphincter-sparing surgery use among patients diagnosed with rectal 
cancer. The statistical analyses used in this study were logistic regression, and all analyses were 
conducted using SAS.  
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CHAPTER 4: RESEARCH FINDINGS  
Aim 1: The Prevalence of Colorectal Cancer Screening by Rural and Urban 
Status in Nebraska  
Members Eligible for Colorectal Cancer Screening by Demographic Characteristics   
As shown in Figure 10 (Aim 1 Study Sample Selection Chart), a total of 105,148 individuals 
met the eligibility criteria for this aim: aged 50-64 years, active members of BCBSNE during the 
study period (2012-2016), and are of average risk of developing CRC. Table 4 compares the 
characteristics of rural and urban members. Despite the statistically significant differences 
between the rural and urban populations, the two populations share similar characteristics. For 
instance, the majority of the two populations visit the PCP (82% and 83%). 
Table 4: BCBSNE Members Eligible for Colorectal Cancer Screening by Rural/Urban Residence 
(N=105,148). 
Characteristics  
Rural 
(n=52,469) 
Urban 
(n=52,673) 
P-value 
Age     
50-54 18365 (35.0) 18977 (36.0) 0.002 
55-59 17702 (34.0) 17476 (33.0)  
60-64 16402 (31.0) 16220 (31.0)  
Gender     
Female 27847 (53.0) 29172 (55.0) <.0001 
Male 24622 (47.0) 23501 (45.0)  
PCPs visits    
Yes 42870 (82.0) 43497 (83.0) 0.0002 
No    9599 (18.0)    9176 (17.0)  
CCI     
0 35739 (68.0) 35546 (67.0) 0.0004 
1   9319 (18.0)   9235 (18.0)  
≥2   7411 (14.0)   7892 (15.0)  
Rural, urban status: 6 observations with missing values 
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Annual FOBT Use 
Table 5 shows the annual FOBT use. During the period 2012-2016, the annual number of 
members eligible for CRC screening fluctuated between 67,821 in the year 2012 to 79,544 in the 
year 2014. In all years except in 2016, the number of eligible members was larger for rural 
compared to urban areas. Overall, there was a small but significant decrease in the use of FOBT 
between 2013 (11%) and 2016 (10%). Table 5 and Figure 16 display the results across all years. 
One of the hypotheses under Aim 1 was that FOBT screening rate would be higher in the rural 
population compared to the urban population. Findings suggest that rural members had higher 
percentages of FOBT use (e.g., 11.39% vs. 10.76% in 2012) compared to urban members (P<.05).  
Rural members had a consistently higher FOBT use for age groups 50-54 and 55-59, but 
this pattern was reversed for the oldest age group of 60-64 years during the year 2016, where the 
rural members had a higher use of FOBT. In rural areas, females had a consistently higher use of 
FOBT compared to males. For instance, in 2012, 15% of females used FOBT while only 7% of males 
used FOBT in rural areas.  In urban areas, the use of FOBT was similar between males and females.  
For both rural and urban areas, PCP visits were also related to the use of FOBT but with different 
size of association. In rural areas in 2012, 12% of those who had PCP visits used FOBT while only 
6% of those without PCP visits used FOBT. A similar pattern was observed for urban areas. 
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Table 5. Annual Percentage of FOBT Use by Rural-urban Status, BCBSNE 2012–2016 (Aim 1) 
 
2012 
(n=8,527) 
2013 
(n=8,827) 
2014 
(n=8,716) 
2015 
(n=7,870) 
June, 2016 
(n=7,229) 
      
Overall by location 
Rural 
(n=4,706) 
Urban 
(n=3,821) 
Rural 
(n=4,827) 
Urban 
(n=4,000) 
Rural 
(n=4661) 
Urban 
(n=4,055) 
Rural 
(n=4,066) 
Urban 
(n=3,804) 
Rural 
(n=3,750) 
Urban 
(n=3,479) 
           
Characteristics 
11.39  
(11.09,11.7) 
10.76  
(10.44,11.0) 
11.54  
(11.24,11.8) 
10.69 
(10.37,11.0) 
11.50  
(11.19,11.8) 
10.39 
(10.09,10.6) 
10.67 
 (10.36,10.98) 
10.23 
(9.92,10.53) 
10.63 
 (10.31,10.95) 
9.47 
(9.17,9.77) 
           
Age        
   50-54 
11.69  
(11.16,12.2) 
9.82 
(9.31,10.35) 
11.80  
(11.29,12.3) 
9.70  
(9.21,10.20) 
11.73  
(11.21,12.2) 
9.40  
(8.92,9.88) 
10.86 
 (10.34,11.38) 
9.30 
(8.82,9.79) 
10.92 
 (10.39,11.46) 
8.77 
(8.30,9.25) 
   55-59 
11.95  
(11.42,12.4) 
11.47  
(10.90,12.0) 
11.94  
(11.41,12.4) 
11.35  
(10.79,11.9) 
11.82  
(11.29,12.3) 
11.01  
(10.48,11.5) 
10.98  
(10.45,11.51) 
10.84  
(10.30,11.38) 
11.01  
(10.47,11.56) 
10.13 
(9.61,10.67) 
   60-64 
10.44  
(9.91,10.97) 
11.09  
(10.50,11.6) 
10.77  
(10.22,11.3) 
11.16  
(10.58,11.7) 
10.83  
(10.27,11.4) 
10.93  
(10.36,11.5) 
10.05 
(9.49,10.62) 
10.69 
 (10.10,11.27) 
9.74 
(9.16,10.33) 
9.58 
(9.02,10.14) 
           
Gender          
   Female 
15.0  
(14.53,15.4) 
10.99  
(10.55,11.4) 
15.18  
(14.71,15.6) 
10.91  
(10.48,11.3) 
15.18  
(14.70,15.6) 
10.61 
(10.20,11.0) 
14.34 
(13.86, 14.82) 
10.53  
(10.11,10.95) 
14.27  
(13.76,14.77) 
9.56 
(9.16,9.97) 
   Male  
7.34  
(6.97,7.70) 
10.47  
(10.0,10.95) 
7.47  
(7.11,7.85) 
10.42  
(9.95,10.88) 
7.40  
(7.03,7.78) 
10.12  
(9.67,10.57) 
6.52 
(6.16,6.88) 
9.85 
(9.40,10.30) 
6.53 
(6.15,6.90) 
9.36 
(8.91,9.81) 
           
PCP visit         
   Yes 
12.27  
(11.92,12.6) 
11.90  
(11.54,12.2) 
12.32  
(11.98,12.6) 
11.69  
(11.34,12.0) 
12.29  
(11.94,12.6) 
11.47  
(11.14,11.8) 
11.45 
 (11.10,11.80) 
11.35  
(11.01,11.70) 
11.52 
 (11.16,11.88) 
10.90  
(10.55,11.24) 
   No 
6.40  
(5.79,7.02) 
2.58 
(2.11,3.05) 
6.75  
(6.10,7.39) 
2.62  
(2.13,3.11) 
6.49  
(5.84,7.15) 
2.18 
(1.76,2.61) 
6.02 
(5.39,6.67) 
1.97 
(1.56,2.38) 
5.63 
(5.01,6.25) 
1.40 
(1.09,1.71) 
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Annual Colonoscopy Screening Use 
Overall, colonoscopy use increased slightly from 14% in 2012 to 15% in 2015. Table 6 and 
Figure 16 display the results across all years. The third row of Table 6 shows the annual 
colonoscopy use by rural and urban status. One of the hypotheses under Aim 1 was that 
colonoscopy rate would be higher in the urban population compared to the rural population.  We 
found that urban members had significantly higher percentages of colonoscopy use compared to 
rural members (P<.001). The proportion of individuals who used colonoscopy was highest in the 
youngest group (50-54 years) and lowest in the oldest group in both rural and urban areas. For 
example, in 2012 in rural areas, 17% of people aged 50-54 used colonoscopy compared to only 
9% of people aged 60-64 years. Similarly, in 2012 in urban areas, 18% of people aged 50-54 used 
colonoscopy while only 11% of people aged 60-64 used colonoscopy.  
In both rural and urban areas and across years, females had higher use of colonoscopy 
compared to males. Moreover, among females, there were significant differences between rural 
and urban areas where females who reside in urban areas had higher colonoscopy use; but the 
magnitude of differences was small. Likewise, among males, there was small magnitude of 
differences in the annual colonoscopy use. Further, we found differences between members who 
had PCP visits compared to those who did not, and the differences were large (e.g., 15% vs. 5% in 
2012).  Among members who visited PCPs, urban members had higher colonoscopy use compared 
to rural members. However, among members with no PCP visits, there were no differences 
between rural and urban areas in the use of colonoscopy.  
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Table 6: Annual Percentage of Colonoscopy Use by Rural-Urban Status, BDBSNE 2012-2016 (Aim 1) 
 2012 
(n=10,855) 
2013 
(n=11,421) 
2014 
(n=11,594) 
2015 
(n=11,164) 
June, 2016 
(n=10,502) 
      
Overall by location 
Rural 
(n=5,595) 
Urban 
(n=5,258) 
Rural 
(n=5,757) 
Urban 
(n=5,662) 
Rural 
(n=5,721) 
Urban 
(n=5,871) 
Rural 
(n=5,473) 
Urban 
(n=5,689) 
Rural 
(n=5,116) 
Urban 
(n=5,385) 
           
Characteristics 
13.55 
(13.22,13.88) 
14.81 
(14.44,15.18) 
13.77 
(13.44,14.10) 
15.13 
(14.77,15.49) 
14.12 
(13.78,14.46) 
15.05 
(14.69,15.40) 
14.37 
(14.01,14.72) 
15.29 
(14.93,15.66) 
14.50 
(14.13,14.87) 
14.66 
(14.30,15.03) 
           
Age           
   50-54 
16.77 
(16.17,17.38) 
17.59 
(16.93,18.25) 
16.89 
(16.29,17.49) 
17.94 
(17.30,18.85) 
17.23 
(16.62,17.84) 
17.80 
(17.18,18.43) 
17.63 
(17.0,18.27) 
18.03 
(17.39,18.67) 
17.75 
(17.09,18.4) 
17.44 
(16.80,18.08) 
   55-59 
14.31 
(13.73,14.89) 
15.47 
(14.82,16.13) 
14.33 
(13.76,14.90) 
15.54 
(14.91,16.18) 
14.56 
(13.98,15.15) 
15.26 
(14.64,15.87) 
14.67 
(14.07,15.26) 
15.38 
(14.75,16.01) 
14.87 
(14.25,15.50) 
14.63 
(14.01,15.24) 
   60-64 
8.98 
(8.48,9.48) 
10.83 
(10.25,11.42) 
9.37 
(8.86,9.88) 
11.21 
(10.63,11.80) 
9.70 
(9.16,10.23) 
11.35 
(10.77,11.93) 
9.85 
(9.29,10.41) 
11.69 
11.08,12.30) 
9.72 
(9.14,10.31) 
11.12 
(10.52,11.72) 
           
Gender            
   Female 
14.56 
(14.10,15.04) 
15.94 
(15.42,16.45) 
14.83 
(14.36,15.30) 
16.28 
(15.78,16.78) 
15.21 
(14.73,15.69) 
16.22 
(15.73,16.72) 
15.33 
(14.83,15.82) 
16.45 
(15.95,16.96) 
15.40 
(14.89,15.92) 
15.53 
(15.03,16.02) 
   Male 
12.40 
(11.94,12.87) 
13.42 
(12.89,13.95) 
12.58 
(12.11,13.04) 
13.71 
(13.19,14.23) 
12.90 
(12.43,13.38) 
13.59 
(13.08,14.10) 
13.28 
(12.78,13.77) 
13.87 
(13.34,14.39) 
13.48 
(12.96,14.0) 
13.58 
(13.05,14.11) 
           
PCP visit           
   Yes 
15.08 
(14.71,15.46) 
16.23 
(15.82,16.64) 
15.16 
(14.79,15.53) 
16.35 
(15.95,16.75) 
15.46 
(15.08,15.84) 
16.35 
(15.96,16.75) 
15.84 
(15.45,16.24) 
16.66 
(16.26,17.06) 
16.13 
(15.72,16.55) 
16.46 
(16.05,16.87) 
   No 
4.76 
(4.23,5.29) 
4.58 
(3.96,5.20) 
5.21 
(4.64,5.78) 
5.24 
(4.56,5.97) 
5.52 
(4.92,6.13) 
5.11 
(4.47,5.75) 
5.51 
(4.90,6.12) 
5.28 
(4.63,5.94) 
5.33 
(4.73,5.94) 
4.46 
(3.91,5.0) 
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Figure 16.  Annual Colonoscopy and Fecal Occult Blood Test in BlueCross BlueShield Nebraska 
Population, 2012-2016 
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Logistic Regression to Examine the Effect of Rural-Urban Status on FOBT Use 
Logistic regression was used to assess the association between the prevalence of CRC 
screening and the individual place of residence (rural or urban), and to compute the odds ratios 
(ORs) and the 95% confidence intervals (CIs). Tables 7 and 9 show the ORs and the 95% CIs at the 
univariate and the multivariate levels. The models were adjusted for age122,188-190, gender122,189,191, 
PCPs visits120,189,192 and CCI56,193,194 based on prior literature demonstrating their association with 
CRC screening.    
As shown in Table 7, at the univariate level, rural population was 51% more likely to use 
FOBT compared with the urban population. The female sex was associated with higher FOBT use 
and the PCP visits (up to 5 visits during 2013-2014) were associated with higher FOBT use. 
Multivariate analysis shows that rural members were 56% more likely to use FOBT compared with 
their urban counterparts: [OR=1.56 (95% CI: 1.45, 1.69)]. The PCP visits was also significantly 
associated with the FOBT use. Members who visited PCPs were more likely to use FOBT compared 
to those who did not, and the FOBT use is higher among members with more PCP visits [OR=1.37 
(95% CI: 1.21, 1.56)].   
Moreover, because we identified interaction between rural-urban status and age, gender 
and PCP visits, we stratified the analyses by these variables as displayed in Table 8.  Among the 
urban population, those who are 55-59 or 60-64 were more likely to use FOBT compared with 50-
54 years old [OR=1.20 (95% CI: 1.01, 1.41) and OR=1.30 (95% CI: 1.10, 1.54)]. Additionally, females 
who live in urban areas were 15% more likely to use FOBT compared with males [OR=1.20 (95% 
CI: 1.01, 1.41)], while those who live in rural areas were 68% less likely   to use FOBT compared 
with males [OR=0.32 (95% CI: 0.28, 0.36)].  Finally, PCP visits of up to 5 times within 2 years was 
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associated with higher FOBT in the rural area while PCP visits was consistently (even > 5 visits) 
associated with higher FOBT use in the urban area compared with no visits. 
Table 7. Univariate and Multivariate Analyses of Variables Associated with FOBT Screening 
Using Logistic Regression Models, BCBSNE 2013-2015 (Aim 1). 
 FOBT use in 2015 
 FOBT use   No FOBT use   P-
value 
Univariate  
OR (95% CI) 
Multivariate 
OR (95% CI)  
Age       
50-54 729 (29.0) 17785 (32.0) 0.03 1.0 1.0 
55-59 891 (36.0) 20056 (36.0) 1.08 
(0.98,1.20) 
1.05 
(0.95,1.17) 
60-64 863 (35.0) 18450 (33.0) 1.14 
(1.03,1.26) 
1.08 
(0.97,1.19) 
Gender       
Male 803 (32.0) 26441 (47.0) <.0001 1.0 1.0 
Female   1680 (68.0) 29850 (53.0)  1.85 
(1.69,2.04) 
1.85 
(1.69,2.0) 
Member Status       
Urban    952 (38.0) 27334 (49.0) <.0001 1.0 1.0 
Rural  1531 (62.0) 28955 (51.0)  1.51 
(1.41,1.67) 
1.56 
(1.45,1.69) 
      
PCP visits in 
2013-2014 
     
0     396 (16.0)     12703 (23.0) <.0001 1.0 1.0 
1 to 2     646 (26.0)     15062 (27.0) 1.38  
(1.21,1.56) 
1.37 
(1.21,1.56) 
3 to 5     733 (30.0)     14796 (26.0) 1.59 
 (1.40,1.80) 
1.59 
(1.40,1.80) 
6 to 9    457 (18.0)       8490 (15.0) 1.73  
(1.50,1.98) 
1.71 
(1.49,1.96) 
≥10    251 (10.0)         5240 (9.0)  1.54  
(1.31,1.81) 
1.49 
(1.26,1.75) 
CCI in 
2013-2014  
     
0 1929 (78.0)     43847 (78.0) 0.92 1.0 1.0 
1   373 (15.0)       7299 (15.0) 1.02 
(0.91,1.14) 
0.99 
(0.87,1.11) 
≥2      181 (7.0)         4145 (7.0) 0.99 
(0.85,1.16) 
0.95 
(0.81,1.11) 
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Table 8. Adjusted association between rural-urban status and FOBT use by age, gender and 
PCP visits. 
Rural-urban status  
Rural-urban status  
Age  
50-54 55-59 60-64 
Rural 1.0 0.97 (0.86,1.11) 0.96 (0.84,1.09) 
Urban 1.0 1.20 (1.01,1.41) 1.30 (1.10,1.54) 
    
 Gender 
 Male Female 
Rural 1.0 0.32 (0.28,0.36) 
Urban 1.0 1.15 (1.01,1.31) 
   
 PCP visits in 2013-2014 
 0 1 to 2 3 to 5 6 to 9 ≥10 
Rural 1.0 1.33 
(1.15,1.55) 
1.38 
(1.18,1.60) 
1.19 
(0.99,1.42) 
1.01  
(0.81,1.25) 
Urban 1.0 1.60 
(1.25,2.05) 
2.33 
(1.84,2.94) 
3.23 
(2.53,4.12) 
3.02  
(2.29,3.98) 
Adjusted for age, gender, PCP visits and CCI. 
 
 
Logistic Regression to Examine the Effect of Rural-Urban Status on Colonoscopy Screening Use 
As shown in Table 9, at the univariate level, the urban population was 9% more likely to 
use colonoscopy compared with the rural population. The male sex was associated with lower 
colonoscopy use while the PCPs visits 2013-2014 were associated with higher colonoscopy use. 
Multivariate analysis shows that female members were 16% more likely to use colonoscopy 
compared with male members: [OR=1.16 (95% CI: 1.09, 1.25)]. There was near significant increase 
in the odds of colonoscopy use among urban versus rural population [OR=1.06 (95% CI: 0.98, 
1.14)]. The PCP visits was also significantly associated with the colonoscopy use. Members who 
visited PCPs were more likely to use colonoscopy compared to those who did not, and the 
colonoscopy use was higher among members with more PCP visits [OR=1.36 (95% CI: 1.21, 1.52)].  
Furthermore, the results of the stratified analyses by age are displayed in Table 10.  
Among the rural population, those who are 55-59 or 60-64 were less likely to use colonoscopy 
compared with 50-54 years old [OR=0.63 (95% CI: 0.55, 0.71) and OR=0.64 (95% CI: 0.56, 0.72)].  
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Likewise, in the urban area, those who are 55-59 or 60-64 were less likely to use colonoscopy 
compared with 50-54 years old [OR=0.43 (95% CI: 0.38, 0.49) and OR=0.67 (95% CI: 0.59, 0.75)].  
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Table 9. Univariate and Multivariate Analyses of Variables Associated with the Use of 
Colonoscopy Using Logistic Regression Models, BCBSNE 2013-2015 (Aim 1). 
 Colonoscopy use in 2015 (Limited to screening colonoscopy) * 
 Colonoscopy 
use   
No Colonoscopy 
use   
P Univariate  
OR (95% CI) 
Multivariate 
OR (95% CI)  
Age       
50-54 1308 (43.0) 17206 (31.0) <.0001 1.0 1.0 
55-59   809 (27.0) 20138 (36.0) 0.53  
(0.48,0.58) 
0.56 
(0.60,0.71) 
60-64   926 (30.0) 18387 (33.0) 0.66  
(0.61,0.72) 
0.86 
(0.80,0.93) 
Gender       
Male 1297 (43.0) 25947 (47.0)  1.0 1.0 
Female  1746 (57.0) 29784 (53.0) <.0001 1.18 
(1.09,1.26) 
1.16 
(1.09,1.25) 
Member Status       
Rural  1515 (50.0) 28971 (52.0) 0.02 1.0 1.0 
Urban  1528 (50.2) 26758 (48.0) 1.09  
(1.01,1.17) 
1.06 
(0.98,1.14) 
PCP visits in 
2013-2014 
     
0      521 (17.0)     12578 (23.0) <.0001 1.0 1.0 
1 to 2      834 (27.0)     14874 (27.0) 1.35 
(1.21,1.51) 
1.36 
(1.21,1.52) 
3 to 5      895 (29.0)     14634 (26.0) 1.48 
(1.32,1.65) 
1.51 
(1.35,1.68) 
≥6      793 (26.0)     13645 (24.0) 1.40 
(1.25,1.57) 
1.47 
(1.31,1.65) 
CCI in 
2013-2014  
     
0    2415 (79.0)     43361 (78.0) 0.03 1.0 1.0 
1      439 (14.0)       8233 (15.0) 0.95  
(0.86,1.06) 
0.95 
(0.85,1.05) 
≥2         189 (6.0)         4137 (7.0) 0.82  
(0.70,0.95) 
0.84 
(0.71,0.97) 
*ICD DX codes for screening: 'V7651','Z1211','V7641','Z1212' 
 
Table 10. Adjusted association between rural-urban status and colonoscopy use by age. 
Rural-urban status  
Rural-urban status  
Age  
50-54 55-59 60-64 
Rural 1.0 0.63 (0.55,0.71) 0.64 (0.56,0.72) 
Urban 1.0 0.43 (0.38,0.49) 0.67 (0.59,0.75) 
Adjusted for age, gender, PCP visits and CCI. 
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Aim2: The Impact of Travel Time on the Metastatic Stage at Diagnosis of 
CRC 
As shown in Figure 12 (Aim 2 Study Sample Selection Chart), a total of 307 individuals met 
the eligibility criteria for this aim: aged 50-64 years, active members of BCBSNE during the study 
period (2012-2016), had CRC diagnosis, and continuously enrolled for at least six months before 
CRC diagnosis.  
Univariate and Multivariate Analysis of Travel Time Analysis for Metastatic Stage at Diagnosis of 
CRC  
A total of 204 members were eligible for travel time analysis of whom 27 had metastatic 
CRC and 177 had metastatic CRC (Table 11). Note the sample included BCBS members diagnosed 
with CRC who had colonoscopy claim within four months before CRC diagnosis by metastatic 
status. The average travel time among the 204 members with colonoscopy was 34 minutes 
(SD=45). Approximately 25% of the members traveled within a time that is more than the mean 
travel time. The relationship between travel time or rurality and metastatic CRC diagnoses were 
not statistically significant. Therefore, the hypothesis “Shorter travel time to colonoscopy facility 
is associated with a non-metastatic diagnosis of CRC” was rejected. Also, for those who do not 
use preventive service, the odds of being diagnosed with metastatic CRC is 2.80 (95% CI: 1.00, 
7.90) times larger than those who used preventive services. 
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Table 11. Univariate and Multivariate Analysis of Metastatic CRC Diagnosis (N=204) (Aim 2). 
 Metastatic  
(n=27) 
Non-Metastatic 
(n=177) 
Univariate 
Model 
 Multivariate 
Model  
 
No 
% or 
SD 
No 
% or 
 SD 
Odds Ratio 
(95% CI) 
P Odds Ratio 
(95% CI) 
Age (year), 
mean  57.56 4.56 57.48 4.15 
1.004 
(0.91,1.01) 
0.91 
 
Gender       
  
     Male 17 63.0 95 54.0 1.0  1.0 
     Female     10 37.0 82 46.0 
0.68 
(0.29,1.57) 
0.37 0.76 
 (0.32, 1.80) 
Member 
location  
     
 
 
     Rural  11 41.0 99 56.0 1.0   
     Urban 16 59.0 78 44.0 
1.84 
(0.82,4.20) 
0.14 2.14  
(0.87,5.30) 
Travel time 
(min), mean 
34.85 51.53 33.38 38.12  
 
1.0 
Travel time  
median (IQR) 18.0 17.0 19.0 28.0 
1.001 
(0.99,1.01) 
0.74 0.99  
(0.98,1.01) 
Preventive  
services  
    
  
 
     Yes  5 19.0 69 39.0 1.0  1.0 
     No 
22 81.0 108 61.0 
2.81  
(1.02,7.77) 
0.04 2.80  
(1.00,7.90) 
      
  
Aim3: Rural-Urban Differences in Healthcare Utilization Among CRC 
Patients 
Hospital Readmission Following CRC Surgery 
The first hypothesis under Aim 1 was “Urban CRC patients who undergo surgery are more 
likely to have lower hospital readmission and emergency department visits.” As shown in Figure 
13, the sample for this hypothesis consists of 315 patients who met the following eligibility 
criteria: aged 50-64 years, active members of BCBSNE during the study period (2012-2016), had 
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CRC diagnosis, continuously enrolled for at least six months before CRC diagnosis, and had CRC 
surgery claims. The 30-day hospital readmission rate for this sample was 20%. The characteristics 
of patients readmitted and those non-readmitted within 30 days of index surgery are presented 
in Table 12. Readmitted patients were more likely to have higher Charlson Comorbidity Index 12 
months prior to index surgery and with the slightly higher length of hospital stay after the 
procedure. For instance, 18% of patients who were readmitted have had >1 comorbidities 12 
months prior to index surgery versus only 7% of non-readmitted patients. There were no 
statistically significant differences between the readmitted and non-readmitted patients 
regarding age, gender, geographic location and travel time to the surgical facility. The median 
length of stay was five days for readmitted patients versus four days for non-readmitted patients 
although the results did not meet the 0.05 level of significance.  
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Table 12. Patients Characteristics By 30-Days Readmission Status for Patients Who Survived 
Index Hospitalization For Colorectal Cancer, BCBSNE 2012-2016 (Aim 3-H1, N=315) 
 Readmitted Non-readmitted  P 
 No  % or SD No  % or SD 
 
Overall  62 20 253 80  
      
Age, mean  54 8.32 53.95 7.96 0.92 
     
Gender      
     Female 24 39 105 42 0.69 
     Male  38 61 148 58 
      
Member Location       
     Rural  26 42 135 53 0.11 
     Urban  36 58 118 47 
      
Distance to provider      
     Mean 21.91 26.25 22.78 40.31 0.29 
     Median  16.00 19.50 11.05 21.75 
      
Travel time       
     Mean 27.69 27.19 27.92 40.46 0.22 
     Median 21.00 24.00 17.00 24.00 
      
Length of stay      
     Mean  6.42 5.21 5.46 5.72 0.07 
     Median  5.00 5.00 4.00 3.00 
      
Charlson Comorbidity Index  
prior to surgery   
     
     0 33 53 171 68 0.02 
     1 18 29 64 25 
     >1 11 18 18 7 
 
A further analysis was conducted to compare characteristics of index surgery between 
patients with readmission and patients without readmission (Table 13). There were no significant 
differences between readmitted and non-readmitted patients in the site of the tumor, the site of 
surgery or whether the patients underwent stoma. However, readmitted patients were more 
likely to have undergone open surgery and were more likely to have presented with obstructed 
or perforated colon. Specifically, 77% of the readmitted patients underwent open CRC surgery 
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while only 50% of the non-readmitted patients underwent open CRC surgery. Furthermore, 58% 
of the readmitted patients had obstructed or perforated intestine during the index surgery versus 
16% for non-readmitted patients. 
Table 13. Index Surgery Characteristics By 30-Days Readmission Status for Patients Who 
Survived Index Hospitalization For Colorectal Cancer, BCBSNE 2012-2016 (Aim 3-H1, N=315) 
 Readmitted  Non-Readmitted  
 
 No  %  No  %  P 
Tumor location       
     Colon  38 61 168 66 0.45 
     Rectum  24 39 85 34  
      
Surgery site      
     Proximal  12 19 45 18 0.95 
     Distal  23 37 97 38  
     Rectal /other 27 44 111 44  
      
Surgery approach       
     Laparoscopic  14 23 127 50 <0.0001 
     Open 48 77 126 50  
      
Intestinal obstruction or 
perforation on admission 
     
     Yes  36 58 41 16 <0.0001 
     No  26 42 212 84  
      
Stoma creation       
     Yes  22 35 61 24 0.07 
     No  40 65 192 76  
 
After adjusting for Charlson Comorbidity Index, surgical approach and obstruction status 
there was no evidence of a difference in the odds of readmission for rural versus urban patients 
(Table 14). Therefore, the hypothesis about the rural and urban difference for readmission was 
rejected. Patients with Charlson Comorbidity Index >1, those with the open procedure and those 
who presented with obstruction or perforation at the time of surgery were more likely to be 
readmitted.   
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Table 14. Multivariable Analysis of Risk Factors for 30-Day Readmission, BCBSNE 2012-2016 
(Aim 3-H1). 
 OR (95% CI) 
Member Location    
     Rural  1.0  
     Urban  1.81 (0.96,3.42) 
   
Charlson Comorbidity Index   
     0 1.0  
     1 1.11 (0.45,2.30) 
     >1 3.59 (1.41,9.11) 
   
Surgery approach    
     Laparoscopic  1.0  
     Open 2.80 (1.39,5.63) 
   
Intestinal obstruction or 
perforation on admission 
  
     No 1.0  
(3.75,13.72)      Yes 7.17 
 
The Utilization of CRC Surgery Among Patients with Metastatic CRC  
The second hypothesis under Aim 3 was “Among patients with metastatic CRC, the 
proportion who undergo surgery is higher among the urban population compared with the rural 
population.” As shown in Figure 14, the sample for this hypothesis consists of 69 patients who 
met the following eligibility criteria: aged 50-64 years, active members of BCBSNE during the study 
period (2012-2016), had metastatic CRC diagnosis and continuously enrolled for at least six 
months before CRC diagnosis.  
Current NCCN guidelines recommend that patients with symptomatic mCRC undergo PTR. 
Asymptomatic patients can be treated with either systemic therapy or surgical intervention (see 
Chapter 2 for more details). The proportion of rural patients who underwent mCRC surgery is 
significantly lower than the proportion of urban patients with mCRC (Table 15). Therefore, the 
hypothesis was not rejected. For example, 39% of members who underwent metastatic CRC 
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surgery lives in rural areas versus 61% who lives in urban areas.  Patients who underwent mCRC 
surgery tend to be older than 50 years old (87%), male (63%), urban residents (61%), had higher 
Charlson Comorbidity Index 12 months prior surgery (82% for CCI≥1) and were diagnosed with 
colon cancer (73%).     
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Table 15. Characteristics of Patients with Metastatic CRC (mCRC) By Surgery Uptake, BCBSNE 
2012-2016 (N=69) (Aim 3-H2). 
 With mCRC Surgery  No mCRC Surgery  
 No. % / SD No. % / SD P 
Overall  33 47 36 52  
Age (mean) 54.49 8.28 54 8.83 0.81 
<50 4 12 7 19 0.40 
    50-64 29 87 29 80 
Gender       
    Female 12 36 18 50 0.25 
    Male  21 63 18 50 
Member location       
    Rural  13 39 25 69 0.01 
    Urban  20 61 11 31 
CCI      
    0 4 12 11 31 0.08 
    1 18 55 11 31 
    >1 11 33 14 38 
Travel time       
    Mean 30.76 27.23 34.39 36.09 0.93 
    Median(IQR)  22.00 21.00 24.00 38.00 
Primary tumor site       
    Colon  24 73 28 78 0.62 
    Rectum  9 27 8 22 
Site of metastasis       
    Liver  14 42 13 36 0.59 
    Others  19 58 23 64 
No. of metastatic sites      
    1 site  16 48 20 56 0.55 
    >1 site  17 52 16 44 
Access to PCP services      
    Mean (physician/10,000) 11.31 10.35 10.96 8.17 0.86 
     Median(IQR) 8.15 9.11 8.15 10.69 
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Logistic Regression Results of the Receipt of Metastatic CRC Surgery 
After adjusting for gender and Charlson Comorbidity Index (Table 16), urban CRC patients 
were more likely to undergo mCRC surgery compared with rural CRC patients 4.35 (95% CI: 1.40, 
13.49).  
Table 16. Multivariable Logistic Regression for Location Adjusted for Gender and Charlson 
Comorbidity Index, BCBSNE 2012-2016 (Aim 3-H2) 
 OR 95% CI P  
Gender    
     Female 1.0 
0.07 
     Male  2.84 (0.90,8.95) 
Member Location  
 
 
     Rural 1.0 
0.01 
     Urban 4.35 (1.40,13.49) 
Intestinal obstruction or 
perforation on admission 
 
 
     No 1.0 0.34 
     Yes 1.88 (0.52,6.80)  
CCI 
 
 
     0 1.0  
     1    4.36 (1.03,18.53) 0.05 
     >1 2.22 (0.50,9.84) 0.91 
 
Sphincter Sparing Surgery Among Patients with Rectal Cancer  
The last hypothesis for Aim 3 was “Among rectal cancer patients, the proportion who 
undergo sphincter-preserving surgery is higher among the urban population compared with the 
rural population.” As shown in Figure 15, the sample for this hypothesis consists of 90 patients 
who met the following eligibility criteria: aged 50-64 years, active members of BCBSNE during the 
study period (2012-2016), had a rectal cancer diagnosis and continuously enrolled for at least six 
months before CRC diagnosis. Three-quarters of the patients diagnosed with rectal cancer and 
treated surgically underwent sphincter-sparing surgery. There were no significant differences in 
the characteristics of patients including rural residency (Table 17). Therefore, the hypothesis was 
rejected. 
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Table 17. Characteristics of Patients with Rectal Cancer by Type Of Surgery, BCBSNE 2012-2016 
(N=90) (Aim 3-H3)  
Sphincter  
Sparing Surgery  
 Non-Sphincter  
Sparing Surgery  
  
  No. % / SD  No.  % / SD P  
Overall  69 77.0  21 23.0   
       
Age, mean  52.10 8.56  53.38 10.37 0.24 
       
Gender             
     Female 33 48.0  7 33.0 0.24 
     Male  36 52.0  14 67.0 
       
Member Location             
     Rural  33 48.0  10 48.0 0.99 
     Urban  36 52.0  11 52.0 
       
CCI            
     ≤1 32 47.0  9 43.0 0.78 
     >1 37 53.0  12 57.0 
       
Distance to provider (miles)            
     Mean 16.51 16.70  24.61 61.80 0.38 
     Median  12.40 20.50  5.90 16.10 
       
Travel time (minutes)             
     Mean 21.27 18.08  28.33 55.60 0.38 
     Median 19.0 22.0  16.0 25.0 
       
Surgery approach            
     Laparoscopic  39 57.0           11 52.0 0.74 
     Open 30 43.0  10 48.0  
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CHAPTER 5: DISCUSSION   
Summary of Findings  
To our knowledge, this is one of the few published studies that used privately-insured 
data to investigate the differences between the rural and the urban populations in CRC screening 
rates, stage at diagnosis and the receipt of surgery. In this privately insured population, there was 
an overall significant increase in the colonoscopy use between 2012 and 2016 (14% to 15%) and 
an overall decrease in FOBT use between 2013 and 2016 (11% to 10%). While the urban 
population was more likely to use colonoscopy, the rural population was more likely to use FOBT. 
Although the percentage changes in screening were significant, the changes were small. When 
adjusting for covariates, the rural population was 56% more likely to use FOBT compared with the 
urban population.  
Although there was no association between travel time to a colonoscopy facility and 
metastatic stage at diagnosis, we found that patients who had no preventive services (vs. those 
who had preventive services) to be 2.80 times more likely to present with mCRC. Additionally, for 
the utilization of mCRC surgery, we found that the urban population was 4.35 times more likely 
to receive mCRC surgery compared to their rural counterpart, but there was no significant 
difference in the receipt of SSS or the 30 days hospital readmission between the two populations.   
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Colorectal Cancer Screening in BCBSNE Population by Rural and Urban 
Status 
Prior research on CRC indicates that screening reduces both incidence and mortality rates 
by detecting polyps or tumors at a precancerous or early stage.58,195 In spite of the demonstrated 
effectiveness of CRC screening tests, CRC screening rates remain less than optimal. In 2015, only 
62.4% of Americans who were eligible for screening received one of the recommended screening 
tests, which is lower than the 80% target set by the Centers for Disease Control and Prevention’s 
Colorectal Cancer Program.196  
Our findings of the declining use of FOBT and the increasing use of colonoscopy are similar 
to other studies.12,86 These studies have the same age group as our study (50-64 years old). While 
one of the studies used claims data the other used survey data and both used data from earlier 
period (1998-2005). Furthermore, we found that the annual FOBT use was between 10% and 11%, 
which is slightly higher than recent FOBT rates from national surveys. For example, the latest rates 
from BRFSS in 2014 and NHIS in 2015 were 8% and 6%.3,13,16 The differences in FOBT rates could 
be due to the differences between claims and self-reported data such as the survey.197,198 For 
instance, studies that are based on surveys are prone to recall bias.197,198Additionally, some of the 
population surveyed are uninsured or underinsured, which might result in lower screening rates. 
.   
In this study, the annual colonoscopy rates were fluctuating between 14% in 2012 and 
15% in 2016.  Among the Medicare population who were 50-64 years old, Schenck et al. found 
that the annual colonoscopy rates were increasing from 5% in 1998 to 9% in 2005. Their findings 
is the latest comparable rates because recent (non-comparable) rates are based on ten years data 
and combine the endoscopy tests (colonoscopy and sigmoidoscopy), which is hard to compare 
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with the annual rates reported in this study.12,199 For instance, the 2015 NHIS data showed that 
55% of the surveyed individuals (50-64 years old) had used sigmoidoscopy within the past five 
years or used colonoscopy within the past ten years.13 Likewise, the 2012 BRFSS data showed that 
65% of the survey individuals (all age groups) reported that they ever had an endoscopy.87                                      
We examined factors associated with FOBT and colonoscopy use. We found that the FOBT 
screening across age groups did not change between 2012 and 2016. However, age was an 
important factor in the use of colonoscopy because there was a large difference in the use of 
colonoscopy between the younger and older individuals across the years. For instance, in 2016 
the use of colonoscopy was 17% among the 50-54 years old, 15% among the 55-59 years old and 
11% among the 60-64 years old. This pattern observed across the entire study period. It is possible 
that the younger age group are more likely to initiate CRC screening once they turn 50 years old 
compared with older individuals. Furthermore, after adjustment for age, gender and PCP visits, 
there was no difference in the use of FOBT or colonoscopy between males and females. Although 
studies that used data from 1999 or 2000 reported that males were more likely to use screening, 
87,200,201 recent studies from 2012 and 2013 showed no difference in the use of CRC screening 
between males and females.87,88 
When placed in the context of primary care literature, our findings corroborate results 
from several studies.84,179,202,203 In our study, both univariate and multivariate analyses showed 
that higher PCP visits are associated with significantly higher FOBT and colonoscopy screening. 
Ata and colleagues assessed the impact of time since last doctor visit on CRC screening and found 
that the odds of screening decrease according to the last time of doctor’s visit.202 Compared with 
those who had doctor visits more than 2 years, the odds ratio for those with a visit within six 
months, between six months and one year and between 1-2 years were 7.59, 5.86 and 2.76.202 
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Studies from 30 primary care practices found both FOBT and colonoscopy were increasing with 
the increase in the number of PCP visits.203 Moreover, we found that FOBT use is more common 
in women compared to men [OR=1.85 (95% CI: 1.69, 2.0)]. This is similar to other studies that 
assessed the difference in CRC screening between males and females,189,204 though other study 
found similar use.122 We also found that females are more likely to use colonoscopy compared to 
males. This is different from previous studies that found male reported higher use.122,189 Part of 
the inconsistent findings is due to the methodology used in previous studies. For example, some 
studies combined all endoscopy test, others did not distinguish between the purpose of 
colonoscopy test (i.e., screening versus others), while others measure colonoscopy use in previous 
ten years. Our results are not directly comparable with results from survey data because we only 
have access to shorter period (<10 years).      
Travel Time and Metastatic Stage at Diagnosis of CRC 
The reason to conduct this analysis was based on the idea that, unlike Medicare 
population, the younger working-age population are less motivated to travel to a colonoscopy 
facility to receive screening test and therefore are more likely to present with metastatic 
CRC.190,205,206 In the current study, we also examined the roles of the use of preventive services as 
the rural population characteristics are different from the urban population and the access to 
services is a big concern in the rural areas.  
There was no significant association between rural residence and the late stage diagnosis 
of CRC in the current study. This is similar to results from recent studies that used cancer registry 
data from Iowa, Nebraska, and Geogia106,111,118 with the exceptions from a registry study 
conducted in Illinois.207 In addition, our study did not find a significant association between travel 
time and metastatic CRC. The findings from this study confirm the results from studies that used 
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cancer registry data.118,208 It was unexpected to find no association between rurality and distance, 
and late-stage diagnosis especially that BCBSNE rural residents are significantly less likely to 
undergo screening colonoscopy compared with the urban residents. Additionally, survey data 
indicate a lower adherence rate of CRC screening among rural residents compared to urban 
residents.86,88 A potential explanation for the lack of association is because the magnitude of 
difference in screening between the rural and the urban is small (e.g., in 2012 the colonoscopy 
use among rural residents was 13.55% and among urban residents was 14.81%). Subsequently, 
this small difference is not translated into differences in CRC stage at diagnosis. Alternatively, the 
discrepancy could be explained by the differences between registry and claims data versus survey 
data. Surveys might results in potential biases (e.g., recall bias) while registry data, as well as 
claims-based data, are more valid because of the accuracy of reporting for registry and because 
claim’s reimbursement is conditional on patient’s health-encounter.  
Results on the role of preventive services give some insight on the importance of CRC 
prevention. We found that patients who did not use preventive services within 12 months before 
CRC diagnosis were two times more likely to get diagnosed with metastatic CRC compared to 
those who had such services. The result may reflect the notion that cancer screening 
communication between the patient and the provider may occur during an annual checkup or 
other routine care settings.64,209,210 It is also possible that patients who perceive screening as less 
beneficial are less likely to use other types of preventive services.123,211 The health belief model,212 
which was developed to elucidates health behavior changes, has extensively been used in cancer 
screening literature.211,213 Using the model, prior research found that the construct of ‘perceived 
benefits’ to be associated with more screening uptake.188,214-216 This finding is similar to other 
diseases as well (e.g., breast cancer) such that the more health-conscious an individual, the more 
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likely such individual is to seek healthy behaviors including preventive services such as 
screening.194      
Rural-Urban Status and Hospital Readmission After CRC Surgery 
Our retrospective cohort study of the privately-insured adults who were diagnosed with 
CRC and treated surgically over the period from January 2012 to June 2016 resulted in 20% 
readmission rate and 6% emergency department visit. The readmission rates that have been 
reported in the literature are ranging between 9% and 25% and the emergency department visit 
around 7% and 9%.180,181,217 The consequences of readmission can be serious since those 
readmitted within 30 days of the index surgery have 2.44 increased in the odds of mortality 
compared with those who were not readmitted.161 In this study, the rural-urban status was not a 
predictor factor for 30-day hospital readmission. This finding is similar to a study conducted 
among Medicare population that found no differences between the rural and urban populations 
in the 30-day readmission rates.161 However, it is dissimilar to another study which found that 
rural population is more likely to get readmitted.160  
Part of the discrepant findings could be because of different definitions for readmission 
depending on the data source used. For example, National Surgical Quality Improvement Program 
(NSQIP) uses clinical reviewer to check medical records for postoperative complications that 
derive readmission and use phone calls to follow up with patients. However, the University Health 
System Consortium (UHC) database is a discharge billing data set that is limited to inpatient 
records.218  Another difference is that NSQIP defines readmission starting from the date of surgery 
while UHC uses the day after discharge.218 Moreover, surgery volumes were not measured in the 
current study and therefore we were unable to adjust for it in the analysis. 
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Among the risk factors of 30-day readmission identified in this study are the use of open 
surgery approach, Charlson Comorbidity Index (CCI) score of >1 and the presence of obstruction 
or perforation at the time of admission. Since the introduction of laparoscopic CRC surgery in 
1991,219,220 the association between the laparoscopic CRC surgery (versus open approach) and the 
decreased readmission rates has been debated. The impact of the surgical approach on the risk 
of hospital readmission after CRC surgery is somewhat anticipated. Although the laparoscopic 
procedure is associated with longer operation time, several studies have found that the minimally 
invasive laparoscopic approach is associated with favorable outcomes including lower 
readmission rates.180,221 As a result, there has been an increase in the utilization of laparoscopy 
during the CRC surgery (37% in 2008 and 44% in 2011).222 Additional favorable outcomes 
associated with the laparoscopy use are a lower postoperative pain, shorter duration of ileus, 
improved pulmonary function, better overall quality of life during the 30 days postoperatively and 
less postoperative LOS.221 The latter have been found to be associated with lower 30 days hospital 
readmission; in the current study, we found near-significant higher LOS among readmitted 
patients (P=0.07).  
In our study, we found that patients who underwent open surgery had 2.8 the odds of 
being readmitted to the hospital within 30 days of the index surgery compared to those who 
underwent laparoscopic surgery; 2.8 (95% CI: 1.39, 5.63). Congruent with our findings, Damle et 
al. assessed the association between surgery approach and 30 days readmission and found that 
patients who underwent open surgery to be 24% more likely to get readmitted compared to those 
with laparoscopic surgery; 1.24  (95% CI: 1.17, 1.31).102 Likewise, Bartlett et al. found that patients 
who underwent laparoscopic surgery to be less likely to get readmitted; 0.90 (95% CI: 
0.85,0.96).163 However, other studies reported non-significant findings.162,165,167 Therefore, given 
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that the higher the use of the laparoscope the lower the LOS, and that the lower the LOS the lower 
the hospital readmission, the evidence suggests an association between laparoscopic use and the 
lower readmission rate.  
We also found that patients with >1 comorbidity score within 12 months before surgery 
to be 3.59 more likely to get readmitted to the hospital within 30 days after index surgery. Several 
studies from diverse populations found that the higher the comorbidity, the higher the likelihood 
of readmission.159,160,163,223 Comorbidity is associated with higher mortality, lower quality of life 
and higher complications of treatment.224 For instance, Greenblatt and colleagues found that 
patients who were readmitted within 30 days of discharge to be 2.44 more likely to die compared 
to those who were not readmitted after controlling many variables including comorbidities.161   
Lastly, we found that 24% of readmitted patients had obstructed or perforated bowel at 
the time of index surgery. This is slightly higher than some studies,139 but similar to others.225,226 
Part of the differences could be different age groups among these studies. Patients with 
obstructed or perforated bowel were 7.17 more likely to get readmitted to the hospital within 30 
days after index surgery, which is similar to some studies that found worse outcomes associated 
with patients who are presented with obstructed or perforated tumors.155,161  
Rural-Urban Status and Differences in Surgery Utilization Among Patients 
with Metastatic CRC 
Due to the higher likelihood of cure, the current National Comprehensive Cancer Network  
(NCCN) guidelines recommend the surgical resection of the metastatic tumor in CRC patients with 
resectable metastases.67 Several studies have shown a 5-year disease-free survival of 20%, and 
meta-analysis reported a median survival of 38%.227-231 Additionally, numerous studies have 
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demonstrated a 5-year overall survival of up to 71% following resection for patients with liver-
only metastasis.232-234 Almost half of the metastases that occur among CRC patients take place in 
the liver, up to 25% in the lung and the rest occur in other organs. Since most of the CRC deaths 
occur in patients with mCRC and because chemotherapy is not a curative treatment for mCRC, 
surgical intervention is the only cure for mCRC patients.235  
While 61% of our study population who were living in the urban area underwent mCRC 
surgery, only 39% of those who were living in the rural area underwent mCRC surgery. In the 
multivariate analysis, we found that urban population is 4.65 times more likely to receive mCRC 
surgery compared to their rural counterparts. Hu and colleagues assessed the secular trends of 
primary tumor resection among patients with metastatic CRC between 1988 and 2010 using 
elderly population. The authors found a decrease in the surgery use from 67.4% and 57.4%. Half 
of patients who live in the West underwent tumor resection and 15.9% of patients who live in the 
Midwest received the surgery. However, the study didn’t distinguish patients’ rural-urban status. 
There are several possible explanations for the difference in mCRC surgery rates between 
the rural and the urban populations. First, given the complexity of the surgical resection of 
metastatic tumors and the required multidisciplinary expertise especially for rectal cancer,74 rural 
hospitals are possibly less equipped with such resources. Although current treatment guidelines 
will minimize regional variations in surgery uptake, access to technology, surgeon’s supply, and 
patients’ own belief are potential determinants of utilization.73,236 Second, it is possible that some 
patients at rural hospitals presented with asymptomatic unresectable tumors, NCCN guidelines 
recommend against operating on such patients, hence the lower rate of rural surgery reported in 
our study assuming that surgeons adhere to such guidelines. 
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Rural-Urban Status and Differences in Sphincter-Sparing Surgery (SSS) 
Utilization Among Patients with Rectal Cancer 
In resemblance to sphincter-sacrificing surgery, sphincter-sparing surgery (SSS) for rectal 
cancer is associated with comparable oncological outcomes. Both procedures lead to similar rates 
of tumor recurrence and equivalent rates of survival.237 However, SSS is associated with better 
patients’ satisfactions and lower morbidity. For example, the social, psychological and physical 
well-being is better among patients treated with SSS.81,83 Because of the better outcomes 
associated with SSS, the rate of SSS have steadily increased between 1988 and 2006: 27% in 1988 
and 60% in 2006. In our study, the rate of SSS use is 77%.   
We found that the rate of SSS uptake is similar in both the rural and the urban privately-
insured populations. Paquette and colleagues assessed the association between rural residents 
and SSS utilization and found that urban patients are more likely to receive the surgery.108 
Although authors controlled for the effect of hospital procedure volumes, the discrepancy in 
procedure volume between hospitals did not explain the higher SSS uptake in urban residents. 
According to the authors, although the SSS rates increased in both the rural and the urban areas, 
the rates remained higher among the urban population. In our study, given that patients are 
privately-insured, it is possible that the null finding is due to higher access to treatment among 
the rural and urban populations. One also can speculate that the no difference findings in this 
study could be due to an increase in the SSS uptake due to the overall better outcome. 
Strengths and Limitations  
Claims-based data are type of data that issued by institutions and providers for 
reimbursement purposes.238,239 Examples of such institutions are insurance firms, healthcare 
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systems or government agencies. The purpose of collecting the data is for organizing, tracking 
patient health and interaction with the healthcare system. As a result, claims data are not 
collected for research purposes. Instead, the ideal data source for cancer outcome and treatment 
would be the clinical trials. This type of data allows investigators to have detailed clinical 
information about patient’s comorbidities and possible preventive or risk factors.240,241 The lack 
of selection bias in such data ensures that the relationship between predictors and outcome is 
not confounded. Unfortunately, only 3%-5% of adult cancer patients are enrolled in clinical 
trials.242        
Unlike clinical trials, claims-based data represent a large population since they contain 
thousands of insured individuals.239,243 Given that, it is an ideal data source for investigating rare 
outcomes such as cancer. Claims-based data include extensive demographic information, 
procedure and treatment information, and providers or organizational characteristics. Unlike data 
generated from clinical trials, claims data are readily available, relatively less expensive and reflect 
the usual care for patients. Studies that assessed the accuracy of claims data in comparison with 
medical records found high validity.243  
In addition to their uniqueness, claims data have several limitations.238,244,245 They lack key 
clinical variables. For instance, claims data do not contain information about cancer staging 
because the reimbursement process is not conditioned on disease characteristics.238 Further, not 
all diagnoses and procedures are captured in claims data. In general, the higher the 
reimbursement of a specific procedure, the more likely for such procedure to be captured in the 
data. For instance, major surgeries are more likely to be captured while comorbidities are less 
likely. Likewise, lab results that are not covered or reimbursed are usually not captured. 
Moreover, access to claims data can be prohibitive because of the data user agreement, requires 
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substantial learning-curve and programming skills, high patient turn-over, contain procedure 
information but without results, delay in data release (time lag) and the study design might impact 
data sensitivity and specificity. 
Accordingly, there are specific limitations that should be considered when interpreting 
the findings of this study. First, about 2% of BCBSNE members ended their membership during 
December 2014, although the impact is minimal, it is possible that this might have contributed to 
the lower screening rates, compared to the year 2015, especially assuming that some of those 
who left BCBSNE were eligible for CRC screening. Second, because claims data are used mainly for 
billing purposes, they do not distinguish the type of colonoscopy use (screening versus none 
screening).246 However, we were able to exclude high-risk populations (e.g., with previous CRC 
diagnosis, IBD, polyps, and UC) and thus were able to limit our population to average-risk 
individuals who are more likely to use screening colonoscopy. We also restricted our population 
to those with continuous enrollment to ensure that the exclusion criteria were met.  
Third, we excluded 30% of the study sample from the travel time analysis because we 
were not able to identify colonoscopy claims within four months prior to CRC diagnosis for these 
individuals.  A potential explanation is that some of these patients were diagnosed at the time of 
surgery due to an obstructed colon. Nonetheless, excluded cases were not significantly different 
from the ones that were not excluded in all measured characteristics in this study. Fourth, we 
were uncertain about the intent of colonoscopy test because classifications were based on claims 
that occurred within 4-months prior to diagnosis; thus, it is possible that misclassification might 
have occurred if symptoms happened before this time or they have never been captured in the 
data.  Fifth, findings should be interpreted with cautions since the six months period for 
identifying preventive services use might not entirely capture the health behavior of an individual. 
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For instance, one might use more health services only during or after an acute illness and thus, 
will be less likely to be captured within the window of six months. Ideally, we should examine the 
preventive services use within one or two years of CRC diagnosis.56,183 
Sixth, we were unable to adjust for hospital volume when assessing the association 
between rural-urban status and surgery uptake because the hospital data are not linked to 
patient’s data. Seventh, BCBSNE provides no information about the intent of PTR; therefore, it is 
possible that patients could have undergone resection as palliative therapy or PTR with the 
resection of the metastatic tumor as curative intent. Eighth, although the BCBSNE population 
represents the population of Nebraska fairly well, this privately insured population does not 
include the underinsured or uninsured population of Nebraska. Thus, one should be cautious 
when comparing BCBSNE to findings from survey studies that included both insured and 
uninsured populations. Lastly, due to the low statistical powers for aim 2 and aim 3, our findings 
for these aims should be interpreted cautiously.   
The implication of using claims data to answer research question include their effect on 
information bias, selection bias or confounding. For instance, information bias might arise if 
underreported diagnosis or procedure are used which will lead to biased effect estimate. In this 
study, we expect that such bias might lead to non-differential misclassification. Another example 
is the occurrence of confounding by indication. This type of selection bias can occur if patients 
selected for treatment are different from those who are not. The selection process is either 
motivated by clinical indication or via referral (e.g., complex cases are referred to certain 
hospitals).  
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Conclusion  
In our privately-insured population in Nebraska, FOBT screening use is higher among rural 
population while colonoscopy screening is higher among the urban population. There are 
profound disparities by gender, the use of preventive services and by PCP visits. To increase CRC 
screening use, patients should be educated about the benefits of CRC screening including the fact 
that more convenient and less expensive tests are readily available. The discussion can be initiated 
during PCP visits when the use of preventive services is more likely to be discussed at the checkup 
visits. Given that the CRC is a preventable disease, it is also imperative to educate patients about 
the risk factors for CRC since around 40% of the disparities in CRC incidence is attributed to 
differences in the prevalence of risk factors such as smoking, unhealthy diet, and obesity. 247,248 
This study did not find an association between travel time to the colonoscopy service and 
the diagnosis of the metastatic CRC. The fact that 13% of this privately insured working-age 
population present with metastatic CRC suggests some non-compliance with screening 
guidelines. It is also possible that in this young cohort population some cases present with the 
aggressive and fast-growing form of the disease with the potential development of mCRC 
between screening colonoscopies. Nevertheless, it is possible that this working-age population 
faces logistic barriers that prevent them from getting off work to get screened.190,205,206 
Alternately, this young cohort population might have a lower perceived risk of getting CRC 
compared with the older population and thus forgo screening.  
The 30-day readmission occurs in about 20% of our population. The identified predictable 
factors were patients who underwent an open procedure, those presented with obstructed or 
perforated colon and patients with higher comorbidities. Hospital readmission is a quality of care 
indicator for patients with CRC and identifying the most predictor factors is crucial to preventing 
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readmission. For patients diagnosed with mCRC, we found no major differences between patients 
with and those without surgery. Despite that, the urban population is more likely to undergo 
surgery. These findings indicate an underuse of mCRC surgery among the rural population. For 
patients diagnosed with rectal surgery, the majority (77%) underwent SSS, but we did not find an 
association between rural-urban status and the SSS use.  
Implications and Recommendations 
Colonoscopy is the gold standard screening test and all other screening tests with positive 
findings must be followed by colonoscopy. In this study, patients with screening colonoscopy were 
less likely to be diagnosed with metastatic CRC compared with those who used surveillance or 
diagnostic colonoscopy. Accordingly, we recommend alleviating barriers that prevent rural 
patients from getting screening-colonoscopy and therefore increase the likelihood of early 
detection of CRC. Until these obstacles have been lessened, screening with more convenient tests 
should be encouraged. One option would be to encourage the use of mailed FOBT/FIT screening 
test since screening with any test that is recommended by the guidelines is better than no 
screening. This type of CRC screening is more convenient because it is taken at home and does 
not require a visit to the healthcare provider.249  In particular, FIT does not require dietary 
restriction and thus can be easily accepted by patients. Whereas specialists with training in 
colonoscopy are needed, PCPs can prescribe FOBT/FIT tests and thus facilitate more CRC 
screening.  
There are many implications for the associations between rural-urban status and 30-day 
hospital readmission. We found that readmission occurs frequently, and some predictor factors 
are preventable. For instance, patients with ≥2 comorbidities were more likely to be readmitted. 
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Institutions should adopt the use of risk prediction calculator to be able to expect the most 
common readmission predictors.250,251  
For patients diagnosed with mCRC, our findings indicate that there is unawareness or 
disagreement with current guidelines among surgeon in rural areas. The unawareness is 
concerning since the studied patients have similar characteristics.  For patients diagnosed with 
rectal surgery, the study indicates a similar use of SSS between the rural and urban populations. 
More than half of the patients in this study underwent laparoscopic SSS, which found to be 
associated with better oncologic outcomes (e.g., surgical margins or lymph node harvest) 
compared with open surgery. Although not captured in BCBSNE, better outcomes can be achieved 
by the use of robotics.80 
Suggestions for Future Research  
Integrated healthcare or organized delivery system is a network of organizations that 
coordinate continuum of services to a defined population and is willing to be held clinically and 
fiscally accountable for the outcomes and the health status of the population it served.252 In this 
integrated healthcare, we found that members with a higher number of PCP visits had higher 
rates of CRC screening. It is, however, unknown if other unmeasured factors have contributed to 
the increased CRC screening. For example, population outreach efforts (e.g., FIT/gFOB Kit 
distribution) or system that are used to invites for screening could have contributed to the 
increased CRC screening uptake. Future studies should illuminate the mechanism of CRC 
screening uptake other than PCP visits. In this population, it is yet to be determined if other 
mechanisms play a role in CRC screening uptake and the extent of their future potential in CRC 
prevention. Identifying the mechanism of CRC screening and their extent in eliciting CRC screening 
will be useful for interventions to increase public health awareness and uptake of CRC screening.  
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Additional avenues for future research should shed light on the “follow-up screening” 
during the CRC screening detection process. For instance, given the importance of following up 
patients with positive FOBT, it is imperative to see what proportion of such population will 
undergo colonoscopy screening. Because claims data does not report the findings of the tests (i.e., 
positive /negative FOBT), we encourage future researchers to ascertain the proportion of test 
completers through linking claims data with electronic health records. Determining the 
percentage of test completers is feasible in integrated health system such as BCBSNE because 
those with positive FOBT will be more likely, assuming they undergo colonoscopy screening, to 
remain within the same insurers since the majority of follow up colonoscopy occur during the 
three months of positive FOBT.253     
Further, in this study, we found that women are more likely to undergo FOBT test 
compared to men. We also found that there was an interaction between rural-urban status and 
gender such that females in the rural areas are less likely to use FOBT while females in the urban 
areas are more likely to use FOBT. Although this finding has been reported previously, it is unclear 
why such disparity in access to FOBT use exist among women in a privately-insured population. 
Future studies should elucidate factors associated with gender differences in FOBT screening 
among the urban and the rural populations.     
Future studies should also acknowledge the limitations of claims data and work to 
mitigates such limitations. For example, since claims data lack information about the stage at 
diagnosis information, the linkage of Nebraska Cancer Registry with the BCBSNE data in future 
studies is warranted. Unlike claims data, cases ascertainment in registry data is more optimal and 
with less likelihood of selection bias. Although previous research showed that claims data are 
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associated with improved validity using ICD codes,175 registry data is the gold standard and would 
complement the available variables in BCBSNE data.  
The current study was limited to annual screening rates because we had access to 4.5 
years of BCBSNE data. Future studies should obtain 6-11 years of data to measure CRC screening 
rates according to the USPSTF guidelines. Given that sigmoidoscopy is recommended every five 
years, a period of at least six years would be ideal to operationalize sigmoidoscopy use. Likewise, 
the 11 years period would be enough to compute colonoscopy use in this privately-insured 
population. Moreover, future studies with enough data should design a matched retrospective 
cohort study to assess the association between rural-urban status and CRC surgery uptake. 
Specifically, propensity score matching is an ideal approach to compare patients who have 
received CRC surgery from those who have not. Doing so helps to minimize potential confounding 
by indication and make the observed characteristics of the two compared groups similar.  
Lastly, we found that urban population is more likely to undergo mCRC surgery. The 
finding persisted after accounting for the intestinal obstruction or perforation, which we arguably 
assume it distinguishes patients who present with symptomatic and asymptomatic status. 
However, in this study, we were unable to account for the impact of surgery volume (both the 
hospital volume and the surgeon volume) on the receipt of mCRC surgery between the two 
populations.   
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Appendices  
Appendix A. Rural-Urban Commuting Area Codes Definitions 
Category Definition 
A 1-Urban focused 
2-Large Rural City/Town (micropolitan) focused 
3-Small Rural Town focused 
4-Isolated Small Rural Town focused 
B 1-Urban 
2-Large Rural City/Town 
3-Small and Isolated Small Rural Town 
C 1-Urban 
2-Rural City 
D 1-Urban (≥30% of workers go to Census Bureau-defined urbanized area) 
2-Rural City 
E 1-Urban 
2-Large Rural City/Town 
3-Small Rural Town 
4-Isolated Small Rural Town 
F Adding group that is non-urban and non-large rural 
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Appendix B. ICD and CPT Codes 
B1. High-risk groups excluded from the study samples 
High-Risk Group  ICD Diagnosis  
CRC diagnosis 153.0,C183,153.1,C184,153.2,C186,153.3,C187,153.4,C180,153.6,C182, 
153.7,C185,153.8,C188,153.9,C189,154.0,C19,154.1,C20,154.8,C218. 
Polyps diagnosis V1272,Z86010 
Inflammatory 
Bowel Disease  
5551,K5010,5552,K5080,5559,K5090, 5561,K5180, 
5562,K5120,5563,K5130, 5565,K5150,5566,K5100, 
5568,K5180,5569,K5190,5581,K520,5582,K521, 5589,K5289,K529 
 
B2. CRC screening tests 
Test type CPT/ICD Codes 
FOBT and FIT 82270, 82272, G0328, 82274 
Colonoscopy  4521,4522,4523,4525,44388,44389,44392,44393,44394,44397,45355, 
45378,45379,45380,45381,45382,4533,4538,45385,45386,45387. 
 
B3. Diagnosis of CRC 
ICD codes Description  
153.0/C183 Malignant neoplasm of hepatic flexure 
153.1/C184 Malignant neoplasm of transverse colon 
153.2/C186 Malignant neoplasm of descending colon 
153.3/C187 Malignant neoplasm of sigmoid colon 
153.4/C180 Malignant neoplasm of cecum 
153.6/C182 Malignant neoplasm of ascending colon 
153.7/C185 Malignant neoplasm of splenic flexure 
153.8/C188 Malignant neoplasm of other specified sites of large intestine 
153.9/C189 Malignant neoplasm of colon, unspecified site 
154.0/C19 Malignant neoplasm of rectosigmoid junction 
154.1/C20 Malignant neoplasm of rectum 
154.8/C218 
Malignant neoplasm of other sites of rectum, rectosigmoid junction, 
and anus 
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B4. Diagnosis of Metastatic CRC 
ICD codes Description  
1960/C770 
Secondary and unspecified malignant neoplasm of lymph nodes of 
head, face, and neck 
1961/C771 
Secondary and unspecified malignant neoplasm of intrathoracic lymph 
nodes 
1963/C773 
Secondary and unspecified malignant neoplasm of lymph nodes of 
axilla and upper limb 
1965/C774 
Secondary and unspecified malignant neoplasm of lymph nodes of 
inguinal region and lower limb 
1970/C7800 Secondary malignant neoplasm of lung 
1971/C781 Secondary malignant neoplasm of mediastinum 
1972/C782 Secondary malignant neoplasm of pleura 
1973/C7839 Secondary malignant neoplasm of other respiratory organs 
1974/C784 Secondary malignant neoplasm of small intestine including duodenum 
1976/C786 Secondary malignant neoplasm of retroperitoneum and peritoneum 
1977/C787 Malignant neoplasm of liver, secondary 
1978/C7889 Secondary malignant neoplasm of other digestive organs and spleen 
1980/C7900 Secondary malignant neoplasm of kidney 
1981/C7911, C7919 Secondary malignant neoplasm of other urinary organs 
1982/C792 Secondary malignant neoplasm of skin 
1983/C793 Secondary malignant neoplasm of brain and spinal cord 
1984/C7932,C7949 Secondary malignant neoplasm of other parts of nervous system 
1985/C7951,C7952 Secondary malignant neoplasm of bone and bone marrow 
1986/C7960 Secondary malignant neoplasm of ovary 
1987/C7970 Secondary malignant neoplasm of adrenal gland 
19881/C7981 Secondary malignant neoplasm of breast 
19882/C7982 Secondary malignant neoplasm of genital organs 
19889/C7989 Secondary malignant neoplasm of other specified sites 
1990/C800 Disseminated malignant neoplasm without specification of site 
 
 
B5. Colonoscopy claims 
ICD/CPT codes Description  
4521 Transabdominal large bowel endoscopy  
4522 Endoscopy large bowel through stoma  
4523 Colonoscopy  
4525 Colonoscopy large bowel biopsy 
44388 Colonoscopy stoma dx including collection of specimen 
44389 Colonoscopy stoma w/biopsy single/multiple 
44392 Colonoscopy stoma removal of lesion by hot biopsy forceps 
44393 Colonoscopy stoma ablation lesion 
44394 
Colonoscopy stoma w/ removal of tumor, polyp or other lesions by 
snare technique. 
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44397   
Colonoscopy through stoma; with transendoscopic stent placement 
(includes pre-dilation) 
45355 
Colonoscopy rigid or flexible transabdominal via colotomy single or 
multiple 
45378 Colonoscopy flexible dx w/collection of specimens when performed 
45379 Colonoscopy flexible w/removal of foreign body(s) 
45380 Colonoscopy w/biopsy single/multiple 
45381 
Colonoscopy flexible with directed submucosal injection any 
substance 
45382 Colonoscopy flexible w/control bleeding any method 
45383 Colonoscopy flexible proximal splenic flexure with ablation of lesion 
45384 Colonoscopy flexible w/removal lesion by hot biopsy forceps 
45385 
Colonoscopy flexible w/ removal of tumor polyp lesion snare 
technique 
45386 Colonoscopy flexible w/transendoscopic balloon dilation  
45387 
Colonoscopy flexible proximal splenic flexure transendoscopic stent 
placement 
 
 
B6. Use of preventive services 
ICD/CPT codes Description  
V700     Routine general medical examination at a health care facility 
V708 Other specified general medical examinations 
V709     Unspecified general medical examination 
V7231     Routine gynecological examination 
V7232     
Encounter for Papanicolaou cervical smear to confirm findings of recent 
normal smear following initial abnormal  
Z0000     
Encounter for general adult medical examination without abnormal 
findings 
Z008     Encounter for other general examination 
Z0141     Encounter for routine gynecological examination 
Z01411     
Encounter for gynecological examination (general) (routine) with 
abnormal findings 
Z01419     
Encounter for gynecological examination (general) (routine) without 
abnormal findings 
Z0142     
Encounter for cervical smear to confirm findings of recent normal 
smear following initial abnormal smear 
99386 Initial preventive medicine new patient 40-64 
99396 Periodic preventive medicine established patient 40-64 years 
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B7. Colon cancer surgery 
ICD/CPT Description  
4571/0dbe0zz,0db
e3zz,0dbe7zz, 
0dbe8zz 
Open Multi-Segment Resection Of Large Intestine  
4572/0dth0zz, 
0dth7zz, Dth8zz 
Open Cecectomy Nec   
4573/0dtf0zz, 
0dtf7zz, 0dtf8zz, 
0dtk0zz 
Open Right Hemicolectomy Nec 
4574/0dtl0zz, 
0dtl7zz, 0dtl8zz 
Open Transverse Colon Res Nec 
4575/0dtg0zz, 
0dtg7zz, 0dtg8zz 
Open Left Hemicolectmy Nec 
4576/0dtn0zz, 
0dtn7zz, 0dtn8zz 
Open Sigmoidectomy Nec 
4579 Partial Large Intestine Excision NEC/NOS 
4581/0dte4zz Laparoscopic Total Intra-Abdominal Colectomy 
4582/0dte0zz Open Total Intrabdominal Colectomy 
4583/0dte7zz, 
0dte8zz 
Total Abdominal Colectomy Nec/Nos 
1731/0dbe4zz Laparoscopic Multi- Segment Resection Large Intestine 
1732/0dth4zz Laparoscopic Cecectomy   
1733/0dtf4zz Laparoscopic Right Hemicolectomy 
1734/0dtl4zz Laparoscopic Resection Transverse Colon 
1735/0dtg4zz Laparoscopic Left Hemicolectomy 
1736/0dtn4zz Laparoscopic Sigmoidectomy 
1739/0dbe4zz Laparoscopic Partial Excision Large Intestine Nec   
44140 Colectomy Partial W/Anastomosis 
44141 Colectomy Partial W/Skin Level Cecostomy/Colostomy 
44143 Colectomy Partial W/End Colostomy & Closure Of Distal Segment.  
44144 Colectomy Partial W/ Colostomy /Ileostomy & Mucofistula. 
44145 Colectomy Partial W/Coloproctostomy 
44146 Colectomy Partial W/Coloproctostomy & Colostomy 
44147 Colectomy Partial Abdominal & Transanal Approach 
44150 Colectomy Total Abdominal W/O Proctectomy W/ Ileostomy  
44151 Colectomy Total Abdominal W/O Proctectomy W/Continent Ileostomy 
44155 Colectomy Total Abdominal W/Proctectomy W/Ileostomy 
44157 Colectomy Total Abdominal W/Proctectomy Ileoanal Anastomosis 
44158 
Colectomy Total Abdominal W/ Proctectomy Ileoanal Anastomosis & 
Reservoir 
44160 Colectomy Partial W/Removal Terminal Ileum & Ileocolostomy 
44204 Laparoscopic Colectomy Partial W/Anastomosis 
44205 Laparoscopic Colectomy Partial W/ Removal Terminal Ileum  
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44206 
Laparoscopic Colectomy Partial W/End Colostomy & Closure Of Distal 
Segment  
44207 
Laparoscopic Colectomy Partial W/Coloproctostomy Low Pelvic 
Anastomosis 
44208 
Laparoscopic Colectomy Partial W/ Coloproctostomy Low Pelvic 
Anastomosis W/Colostomy 
44210 
Laparoscopic Colectomy Total W/O Proctectomy 
W/Ileostomy/Ileoproctostomy 
44211 
Laparoscopic Colectomy Total Abdominal W/Proctectomy Ileoanal 
Anastomosis 
44212 Laparoscopic Colectomy Abdominal W/Proctectomy W/Ileostomy 
 
B8. Rectal cancer surgery 
ICD/CPT Description  
44145 Colectomy Prtl W/Coloproctostomy. 
44146 Colectomy Prtl W/Coloproctostomy & Colostomy. 
44147 Colectomy Prtl Abdominal & Transanal Approach. 
44155 TPC - Total Proctocolectomy, Ileostomy Includes Stoma. 
44156 TPC - Total Proctocolectomy, Continent Ileostomy Includes Stoma. 
44157 
TPC, IAA - Ileo-Anal Anastomosis, Straight With Or Without Stoma, 
Code Stoma Separately When Done.  
44158 TPC, IPAA - Ileal Pouch-Anal Anastomosis. 
44207 Laps Colectomy Prtl W/Colopxtstmy Lw Anast. 
44208 Laps Colectomy Prtl W/Colopxtstmy Lw Anast W/Clst 
44211 Laps Colct Ttl Abd W/Prctect Ileoanal Anastomosis 
44212 Laparoscopic TPC - Total Proctocolectomy, Includes Stoma 
44238 Unlisted Laparoscopy Procedure, Intestine. 
45499 Unlisted Laparoscopy Rectum. 
45110 Proctectomy , APR, Colostomy Includes Stoma 
45111 Prctect Prtl Rescj Rectum Tabdl Appr 
45112 Prctect Cmbn Abdominoprnl Pull-Thru Px 
45113 Prctect Prtl W/Mucosec Ileoanal Anast Rsvr 
45114 
Proctectomy, Combined Abdominal And Transsacral Approach With Or 
Without Stoma  
45116 
Proctectomy, Partial, Parasacral (Kraske Or York-Mason Approach) 
Anorectal Procedures Transanal Excision 
45119 Prctect Cmbn Pull-Thru W/Rsvr W/Ntrstm 
45120 Prctect Compl W/Pull-Thru Px & Anastomosis 
45121 
Proctocolectomy, For Congenital Megacolon, Including Total Colectomy 
With Pull-Through (Eg, Swenson, Duhamel, Or Soave) With Or Without 
Stoma, Code Stoma Separately When Done 
45123 Prctect Prtl W/O Anast Prnl Appr 
45126 
Pelvic Exenteration For Colorectal Malignancy, With Proctectomy (With 
Or Without Colostomy), With Removal Of Bladder And Ureteral 
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Transplantations, And Hysterectomy, Or Cervicectomy, With Or 
Without Removal Of Tube(S), With Or Without Removal Of Ovary(S),  
45160 Exc Rct Tum Proctotomy Transsac/Transcoccyge 
45170 Excision Of Rectal Tumor, Transanal Approach CPT Expanded 
45171 Exc Rct Tum Not Incl Muscularis Propria 
45172 Exc Rct Tum Incl Muscularis Propria 
45190 Destruction Rectal Tumor Transanal Approach 
45395 Proctectomy, APR, Colostomy, Laparoscopic Includes Stoma 
45999 Unlisted Procedure, Rectum (Open) 
45397 Laps Proctectomy Combined Pull-Thru W/Reservoir 
483 Local Excision Or Destruction Of Lesion Or Tissue Of Rectum 
4831 Radical Electrocoagulation Of Rectal Lesion Or Tissue 
4832, 0d5p0zz, 
0d5p3zz,0d5p4zz, 
0d5p7zz, 0d5p8zz 
Other Electrocoagulation Of Rectal Lesion Or Tissue 
4833 Destruction Of Rectal Lesion Or Tissue By Laser 
4834 Destruction Of Rectal Lesion Or Tissue By Cryosurgery 
4835, 0dbp3zz, 
0dbp7zz, 0dbp8zz 
Local Excision Of Rectal Lesion Or Tissue 
4836, 0dbp4zz, 
0dbp8zz 
[Endoscopic] Polypectomy Of Rectum 
4840,0dtp0zz, 
0dtp4zz 
 Pull-Through Resection Of Rectum, Not Otherwise Specified 
4841  Soave Submucosal Resection Of Rectum 
4842, 0dtp4zz  Laparoscopic Pull-Through Resection Of Rectum 
4843, 0dtp0zz Open Pull-Through Resection Of Rectum 
4849, 0dtp0zz, 
0dtp4zz 
Other Pull-Through Resection Of Rectum 
4850, 0dtp0zz , 
0dtp4zz , 0dtp7zz , 
0dtp8zz, 0d1n0z4 
Abdominoperineal Resection Of The Rectum, Not Otherwise Specified 
4851, 0dtp4zz, 
0d1n0z4 
Laparoscopic Abdominoperineal Resection Of The Rectum 
4852, 0dtp0zz, 
0d1n0z4 
Open Abdominoperineal Resection Of The Rectum 
4859, 0dtp7zz, 
0dtp8zz, 0d1n0z4  
Other Abdominoperineal Resection Of The Rectum 
486 Other Resection Of Rectum 
4861 Transsacral Rectosigmoidectomy 
4862, 0dtp0zz, 
0dtp4zz, 0d1n0z4, 
0d1n4z4  
Anterior Resection Of Rectum With Synchronous Colostomy  
4863, 0dtp0zz, 
0dtp4zz 
Other Anterior Resection Of Rectum 
4864 Posterior Resection Of Rectum 
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4865 Duhamel Resection Of Rectum 
 
B9. Primary Care Physician Codes 
ICD/CPT Description  
001 General practice  
011 Internal medicine  
008 Family practice  
 
 
B10. Stoma Codes 
ICD/CPT Description  
4610, 0D1H0Z4,0D1H4Z4,0D1H8Z4,0D1K0Z4, 
0D1K4Z4,0D1K8Z4,0D1L0Z4,0D1L4Z4,0D1L8Z4, 
0D1N0Z4,0D1N4Z4,0D1N8Z4,4620,0D1B0Z4, 
0D1B4Z4,0D1B8Z4,4621,0D1B0Z4 
,0D1B4Z4,0D1B8Z4, 
Colostomy NOS 
4611 Temporary colostomy 
4613 Permanent colostomy 
4620, 0D1B0Z4,0D1B4Z4,0D1B8Z4 Ileostomy NOS 
V44.2 Ileostomy 
V44.3  colostomy 
4621 Temporary ileostomy 
4623 Permanent ileostomy NEC 
44141 COLECTOMY PRTL W/SKIN LEVEL 
CECOST/COLOSTOMY 
44143 COLECTOMY PRTL W/END COLOSTOMY & 
CLSR DSTL SGMT 
44144 COLECTOMY PRTL W/COLOST/ILEOST & 
MUCOFISTULA 
44146 COLECTOMY PRTL W/COLOPROCTOSTOMY 
& COLOSTOMY 
44150 COLCT TOT ABDL W/O PRCTECT 
W/ILEOST/ILEOPXTS 
44155 COLECTOMY TOT ABDL W/PROCTECTOMY 
W/ILEOSTOMY 
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Appendix C. Sensitivity Analyses  
C1. Definitions to Identify CRC Diagnosis 
C1.1. Definition#1175 
First: Before applying any definition: We identify members 50-64 years old who were continuously 
 enrolled for each single year. For example, there were 113,333 members who were continuously  
enrolled in the year of 2015 (see tables below). For those members, we identify any diagnosis of  
CRC according to the year of diagnosis. For instance, there were 390 members (out of the 113,333 
members) with any CRC diagnosis in the year 2015, 362 in the year 2014 and so on.   
 
Eligibility Criteria       
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015 
N = 113333         
 Any dx of CRC         
  2012 2013 2014 2015    
N 230 269 362 390    
                
Eligibility Criteria    
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014 
N = 119732         
 Any dx of CRC       
  2012 2013 2014     
N 259 312 412     
                
Eligibility Criteria       
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013 
N = 122531        
 Any dx of CRC       
  2012 2013      
N 307 363      
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Eligibility Criteria  
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012 
N = 115474        
  Any dx of CRC       
  2012       
N 336       
 
Second: After applying definition#1 (Among cohort with ≥ 1 CRC DX + any surgery related 
during the same hospitalization and/or visit).  
A total of 241 members 50-64 years old were continuously enrolled for the year 2015 had CRC diagnosis.  
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015 
N = 241         
 Any dx of CRC         
  2012 2013 2014 2015    
N 42 53 72 69    
                
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014 
N = 260         
 Any dx of CRC       
  2012 2013 2014     
N 49 62 80     
                
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013 
N = 266        
 Any dx of CRC       
  2012 2013      
N 57 73      
         
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012 
N = 255        
  Any dx of CRC       
  2012       
N 59       
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Third: Variations in timing of CRC DX according to different periods of continuous enrollment in BCBSNE. 
   Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  
  N  in 2012 in 2012  in 2013 in 2013  in 2014 in 2014  in 2015 in 2015 
Enrolled > 4 months 317 67 67 78 73 89 84 76 69 
Enrolled > 6 months 316 67 67 78 
 
73 89 84 76 69 
Enrolled > 9 months 312 67 67 78 
 
73 87 82 76 69 
Enrolled > 12 months 308 64 64 78 
 
73 87 82 75 68 
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Fourth: Variations in period of continuous enrollment by different CRC-free periods (4-12 months)   
FOR THOSE ENROLLED > 4 MONTHS      
                 Number of cases with at least 1 CRC dx with no other CRC dx in prior 4 months 
 N 2012 2013 2014 2015     
  284 44 72 82 64    
        
        
FOR THOSE ENROLLED > 6 MONTHS      
                 Number of cases with at least 1 CRC dx with no other CRC dx in prior 6 months 
 N 2012 2013 2014 2015    
  267 34 70 78 64   
        
        
FOR THOSE ENROLLED > 12 MONTHS      
                Number of cases with at least 1 CRC dx with no other CRC dx in prior 12 months 
 N 2012 2013 2014 2015    
  222 0 67 73 62   
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C1.2. Definition#2 
First: Before applying any definition (see C1.1. above)  
Second: After applying definition#2 (Among cohort with ≥2 CRC within 2 months). 
Eligibility Criteria        
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015 
N = 414          
 Any dx of CRC          
  2012 2013 2014 2015     
N 124 72 107 71     
         
Eligibility Criteria        
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014 
N = 455          
 Any dx of CRC        
  2012 2013 2014      
N 141 93 115      
         
Eligibility Criteria        
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013 
N = 478         
 Any dx of CRC        
  2012 2013       
N 177 104       
 
 
          
Eligibility Criteria          
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012 
N = 479         
  Any dx of CRC        
  2012        
N 206        
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Third: Variations in timing of CRC DX according to different periods of continuous enrollment in BCBSNE 
   Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  
  N  in 2012 in 2012  in 2013 in 2013  in 2014 in 2014  in 2015 in 2015 
Enrolled >4 months 637 231 231 117 102 141 124 95 86 
Enrolled >6 months 633 229 229 116 101 141 124 95 86 
Enrolled >9 months 613 224 224 116 101 137 120 94 85 
Enrolled >12 months 592 211 211 115 100 134 117 91 82 
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Fourth: Variations in period of continuous enrollment by different CRC-free periods (4-12 months)   
FOR THOSE ENROLLED > 4 MONTHS      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 4 months 
 N 2012 2013 2014 2015     
  456 95 107 127 83    
 
 
FOR THOSE ENROLLED > 6 MONTHS      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 6 months 
 N 2012 2013 2014 2015    
  405 64 103 115 81   
        
FOR THOSE ENROLLED > 12 MONTHS      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 12 months 
 N 2012 2013 2014 2015    
  316 0 95 106 74   
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C1.3. Definition#3 
First: Before applying any definition (see C1.1. above)  
Second: After applying definition#4 (Among Cohort with At Least 1 Inpatient or at Least 2 Outpatient 
Visits with CRC Diagnoses During Study Period). 
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015 
N = 514         
 Any dx of CRC         
  
201
2 
201
3 
201
4 
201
5    
N 201 251 332 369    
                
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014 
N = 562         
 Any dx of CRC       
  2012 2013 2014     
N 226 292 376     
                
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013 
N = 587        
 Any dx of CRC       
  2012 2013      
N 270 337      
 
Eligibility Criteria 
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012 
N = 580        
  Any dx of CRC       
  
201
2       
N 296       
   
128 
 
Third: Variations in timing of CRC DX according to different periods of continuous enrollment in BCBSNE. 
   Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx  Any CRC dx 1st CRC dx 
  N  in 2012 in 2012  in 2013 in 2013  in 2014 in 2014  in 2015 in 2015 
Enrolled >4 months 774 333 333 390 130 437 152 428 105 
Enrolled >6 months 769 330 330 389 129 437 152 428 105 
Enrolled >9 months 744 323 323 389 129 433 148 427 104 
Enrolled >12 months 719 310 310 387 128 428 144 418 98 
Enrolled >18 months 674 289 289 363 123 419 140 403 85 
Enrolled >24 months 611 259 259 326 111 404 130 383 76 
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Fourth: Variations in period of continuous enrollment by different CRC-free periods (4-12 months)   
FOR THOSE ENROLLED > 4 MONTHS: 774      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 4 months 
 N 2012 2013 2014 2015     
  500 129 113 128 88    
                
FOR THOSE ENROLLED > 6 MONTHS: 769      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 6 months 
 N 2012 2013 2014 2015    
  437 83 109 120 85   
        
FOR THOSE ENROLLED > 12 MONTHS: 719      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 12 months 
 N 2012 2013 2014 2015    
  327 0 99 110 79   
        
FOR THOSE ENROLLED > 18 MONTHS: 674      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 18 months 
 N 2012 2013 2014 2015    
  262 0 47 105 74   
        
FOR THOSE ENROLLED > 24 MONTHS: 611      
  Number of cases with at least 1 CRC dx with no other CRC dx in prior 24 months 
 N 2012 2013 2014 2015    
  205 0 0 104 66   
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C2. The impact of sensitivity and specificity of various definitions on the association between travel time and stage at diagnosis. 
Scenario 
travel  
time 
induction 
period 
(cancer-
free) Se* Sp** Metastatic  
Non-
Metastatic total  
Corrected estimates due to  
Misclassifications  
Bias 
direction 
ORcorr† InORm†† up/down 
 
1 
<17 0 1 1 13 88 101 
0.93912 Ref. - - ≥17 0 1 1 14 89 103 
2 
<17 0 0.8118 0.9922 15.19 85.81 101 
0.934 0.006 Up Toward  ≥17 0 0.8118 0.9922 16.41 86.59 103 
3 
<17 6 0.8398 0.9935 14.81 86.19 101 
0.93472 0.005 Up Toward  ≥17 6 0.8398 0.9935 16.00 87.00 103 
4 
<17 6 0.8398 0.97 12.31 88.69 101 
0.92249 0.018 Up  Toward  ≥17 6 0.8398 0.97 13.47 89.53 103 
5 
<17 6 0.6725 0.9935 18.53 82.47 101 
0.93178 0.008 Up  Toward  ≥17 6 0.6725 0.9935 20.02 82.98 103 
6 
<17 12 0.8434 0.9938 14.78 86.22 101 
0.935 0.005 Up Toward  ≥17 12 0.8434 0.9938 15.96 87.04 103 
7 
<17 18 0.8475 0.9938 14.71 86.29 101 
0.93495 0.004 Up Toward  ≥17 18 0.8475 0.9938 15.88 87.12 103 
8 
<17 24 0.8555 0.9939 14.58 86.42 101 
0.935 0.004 Up Toward  ≥17 24 0.8555 0.9939 15.74 87.26 103 
9 
<17 30 0.8579 0.994 14.55 86.45 101 
0.93517 0.004 Up Toward  ≥17 30 0.8579 0.994 15.71 87.29 103 
10 
<17 36 0.8616 0.994 14.49 86.51 101 
0.935 0.004 Up Toward  ≥17 36 0.8616 0.994 15.64 87.36 103 
*Sensitivity,** Specificity, † Corrected odds ratio.†† InORm (Natural log of odds ratio due to misclassification)= Ln(ORobserved/ORcorrected). 
The range of sensitivity and specify were derived from Setoguchi et. al.175  
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C3. The Magnitude of Change in Odds Ratio According to Different Travel Times 
Time variations OR 
Original  0.996 (0.985,1.008) 
1 minute  0.996 (0.985,1.008) 
10 minutes 0.997 (0.985,1.009) 
20 minutes  0.997 (0.985,1.009) 
30 minutes  0.998 (0.986,1.010) 
 
 
C4. Frequency of Colorectal Cancer Cases Identified According to Different Periods of 
Colonoscopy Use 
Continuous enrollment period Total CRC cases  
3 months before or 14 days after CRC diagnosis  200 
4 months before or 14 days after CRC diagnosis 204  
6  months or 14 days after CRC diagnosis 210 
12 months or 14 days after CRC diagnosis 258 
  
 
 
 
 
C5. Identification of Colorectal Cancer Cases According to Periods of Continuous Enrollment 
Continuous enrollment period Total CRC cases  
3 months before CRC Diagnosis  453 
4 months before CRC Diagnosis 429 
6 months before CRC Diagnosis 366 
12 months before CRC Diagnosis 279 
18 months before CRC Diagnosis 228 
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C6. Definitions to Identify Colonoscopy Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identifying Colonoscopy Using Definition 1: Continuous 
Enrollment of ≥6 months (n=269) 
 
Non-metastatic CRC DX 
N= 213 
Metastatic CRC 
N=19 
 
With CRC surgery anytime   
N= 213   
 
No surgery anytime   
N= 0 
 
With CRC surgery within 6 months 
after CRC DX       N= 213   
 
No surgery within 6 months after 
CRC DX      N= 0 
 
4 months pre or 2 weeks post 
CRC DX     N= 198   
 
Any time colonoscopy  
N= 210 
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Identifying Colonoscopy Using Definition 2: Continuous 
Enrollment of ≥6 months (n=735) 
 
Non-metastatic CRC DX 
N= 542 
Metastatic CRC 
N=193 
 
With CRC surgery 
N= 316   
 
No surgery   
N= 226 
 
With CRC surgery 
N= 240   
 
No surgery   
N= 76 
 
4 months pre or 2 weeks 
post CRC DX 
N= 195   
 
Any time colonoscopy  
N= 203 
 
134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identifying Colonoscopy Using Definition 3: Continuous 
Enrollment of ≥6 months (n=735) 
 
Non-metastatic CRC DX 
N= 542 
Metastatic CRC 
N=193 
 
With CRC surgery anytime   
N= 316   
 
No surgery anytime   
N= 226 
 
With surgery within 6 months 
after CRC DX      N= 240   
 
No surgery within 6 months 
after CRC DX      N= 76 
 
4 months before or 2 weeks 
post CRC DX 
N= 209   
 
Any time colonoscopy  
N= 239 
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C7. Definition of CRC Diagnosis by Year of Diagnosis  
BCBS members ages 50-64 - 
continuously enrolled between… 
N Definition 1 Definition 2 Definition 3 
January 1, 2012 - December 31, 2012 115,474 255 479 580 
January 1, 2013 - December 31, 2013 122,531 266 478 587 
January 1, 2014 - December 31, 2014 119,732 260 455 562 
January 1, 2015 - December 31, 2015 113,333 241 414 514 
N: Members who were continuously enrolled during a single year  
Definition 1: Among cohort with ≥ 1 CRC + any surgery related during the same hospitalization 
and/or visit. 
Definition 2: Among cohort with ≥2 CRC diagnosis within 2 months 
Definition 3: Among cohort with at least 1 inpatient or at least 2 outpatient visits with CRC 
diagnoses during the study period. 
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Appendix D. Comparison between the BCBSNE and the State of Nebraska 
Population   
D. Frequencies and Percentages of BCBSNE and The State of Nebraska Population by Regional 
Health Department 
Region  BCBSNE members The State of Nebraska  
 N % N % 
Panhandle Public Health District 25731 3.74 88403 4.85 
North Central District Health 
Department 19938 2.90 46394 2.54 
Northeast Nebraska Public Health 
Department  10331 1.50 31387 1.72 
Dakota County Health Department 2656 0.39 21006 1.15 
West Central District Health 
Department 1584 0.23 39433 2.16 
Loup Basin Public Health 
Department 14229 2.07 31140 1.71 
East Central District Health 
Department 21093 3.06 51992 2.85 
Elkhorn Logan Valley Public Health 
Department 23461 3.41 57002 3.13 
Three Rivers Public Health 
Department 32598 4.74 77705 4.26 
Lincoln/Lancaster County Health 
Department 122961 17.86 285407 15.65 
Sarby/Cass Department of Health 
and Wellness 67846 9.86 184081 10.10 
Douglas County Health Department 189848 27.58 517110 28.36 
Southwest Nebraska Public Health 
Department 18061 2.62 36987 2.03 
Two Rivers Public Health 
Department 38224 5.55 94797 5.20 
South Heartland District Health 
Department 19033 2.77 46218 2.53 
Central District Health Department 26997 3.92 75576 4.14 
Public Health Solutions District 
Health Department  21768 3.16 55176 3.03 
Four Corners  Health Department 17086 2.48 44216 2.42 
Southeast District Health 
Department 14844 2.16 39341 2.16 
Total  673445 100.0 1823371 100.0 
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